<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002923.pub2" GROUP_ID="SCHIZ" ID="498200082810045910" MERGED_FROM="" MODIFIED="2012-11-07 12:18:39 +0000" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;Claudio Ribeiro withdrawn from review&lt;/p&gt;" NOTES_MODIFIED="2012-11-07 12:16:36 +0000" NOTES_MODIFIED_BY="Claire Irving" REVIEW_NO="92" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2012-11-07 12:18:39 +0000" MODIFIED_BY="Claire Irving">
<TITLE>Penfluridol for schizophrenia</TITLE>
<CONTACT MODIFIED="2012-11-07 12:18:39 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="9639" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bernardo</FIRST_NAME><MIDDLE_INITIALS>GO</MIDDLE_INITIALS><LAST_NAME>Soares</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>bgosoares@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT><ORGANISATION>Universidade Federal de São Paulo</ORGANISATION><ADDRESS_1>Rua Pedro de Toledo 598</ADDRESS_1><CITY>São Paulo</CITY><ZIP>04039-001</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5575 2970</PHONE_1><FAX_1>+55 11 5579 0469</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-11-07 12:18:39 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="9639" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bernardo</FIRST_NAME><MIDDLE_INITIALS>GO</MIDDLE_INITIALS><LAST_NAME>Soares</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>bgosoares@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT><ORGANISATION>Universidade Federal de São Paulo</ORGANISATION><ADDRESS_1>Rua Pedro de Toledo 598</ADDRESS_1><CITY>São Paulo</CITY><ZIP>04039-001</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5575 2970</PHONE_1><FAX_1>+55 11 5579 0469</FAX_1></ADDRESS></PERSON><PERSON ID="13374" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Mauricio</FIRST_NAME><LAST_NAME>Silva de Lima</LAST_NAME><SUFFIX>M.D. Ph.D.</SUFFIX><POSITION>Medical Director - Eli Lilly UK &amp; RoI</POSITION><EMAIL_1>msilvadelima@yahoo.com.br</EMAIL_1><EMAIL_2>limama@lilly.com</EMAIL_2><ADDRESS><DEPARTMENT>Medical</DEPARTMENT><ORGANISATION>Eli Lilly &amp; Co</ORGANISATION><ADDRESS_1>Lilly House</ADDRESS_1><ADDRESS_2>Priestley Road</ADDRESS_2><CITY>Basingstoke</CITY><ZIP>RG24 9NL</ZIP><REGION>Hampshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+441256775252</PHONE_1><FAX_1>+441256775441</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-11-07 12:14:55 +0000" MODIFIED_BY="John  Rathbone">
<UP_TO_DATE>
<DATE DAY="10" MONTH="1" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="10" MONTH="1" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="16" MONTH="3" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2012-11-07 12:14:24 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-11-07 12:14:24 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="9" YEAR="2012"/>
<DESCRIPTION>
<P>Update search of Cochrane Schizophrenia Group's Trial Register (see <A HREF="http://archie.cochrane.org/sections/documents/view?version=44705070754671417758120516110605&amp;format=REVMAN#SEARCH_METHODS">Search methods for identification of studies</A>), 8 studies added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="31" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-31 12:07:12 +0000" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Universidade da Região de Joinville - UNIVILLE</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Brazilian Cochrane Centre</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Centro de Medicina Baseada em Evidências - Universidade Federal de Pelotas</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-11-07 12:16:36 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-10-31 12:12:54 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-31 12:05:39 +0000" MODIFIED_BY="[Empty name]">Penfluridol for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2008-10-31 12:12:54 +0000" MODIFIED_BY="[Empty name]">
<P>Synopsis pending.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-11-07 10:41:32 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Penfluridol, available since 1970, is an unusual long acting oral antipsychotic agent for the treatment of schizophrenia. It may be considered a depot medication as it is administered once a week.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To review the effects of penfluridol for treatment of those with schizophrenia and schizophrenia-like illnesses in comparison to placebo, other antipsychotic medication or no intervention.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-11-07 10:40:31 +0000" MODIFIED_BY="[Empty name]">
<P>We undertook electronic searches of the Cochrane Schizophrenia Group's Register (2005), the Cochrane Central Register of Controlled Trials (2003-5) and LILACS (1982-2005). We hand searched references of all identified studies and sought citations of these studies in the Science Citation Index. We contacted the authors of trials and the manufacturer of penfluridol.</P>
<P>We updated this search September 2012 and added eight new trials to the awaiting classification section.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We reliably selected all randomised clinical trials comparing penfluridol to placebo or typical or atypical antipsychotic drugs for schizophrenia or serious mental illness.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We independently extracted and analysed data on an intention-to-treat basis. We calculated the relative risk (RR) and 95% confidence intervals (CI) of homogeneous dichotomous data using a random effects model, and where possible calculated the number needed to treat. We calculated weighted mean differences (WMD) for continuous data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We included twenty-five studies with a total of 1024 participants. Most of these studies were undertaken in the 1970s when penfluridol was launched. Ten studies, with 365 patients, compared penfluridol to placebo. In the meta-analysis of medium-term lasting studies, penfluridol was superior to placebo in the main efficacy measures: 'improvement in global state' (n=159, 4 RCTs, RR 0.69 CI 0.6 to 0.8, NNT 3 CI 2 to 10) and 'needing additional antipsychotic' (n=138, 5 RCTs, RR 0.43 CI 0.2 to 0.8, NNT 3 CI 1.8 to 20).</P>
<P>A total of 449 patients from eleven studies were randomised to penfluridol or oral typical antipsychotics. There were no particular differences between penfluridol versus chlorpromazine, fluphenazine, trifluoperazine, thioridazine, or thiothixene for the main outcome measures in medium-term trials: 'improvement on global state' (N=2 studies), 'leaving the study early' (N=6), 'needing additional antipsychotic' (N=3), needing antiparkinsonian medication (N=2), and side-effects.</P>
<P>Six studies, with 274 patients, compared penfluridol to depot typical antipsychotics. In general, for the efficacy and safety measures, no differences were established, but penfluridol was superior in keeping the patients in treatment; 'leaving the study early' (n=218, 5RCTs, RR 0.55 CI 0.3 to 0.97, NNT 6 CI 3.4 to 50).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-11-07 10:41:32 +0000" MODIFIED_BY="[Empty name]">
<P>Although there are shortcomings and gaps in the data, there appears to be enough overall consistency for different outcomes. The efficacy and adverse effects profile of penfluridol are similar to other typical antipsychotics; both oral and depot. Furthermore, penfluridol is shown to be an adequate treatment option for people with schizophrenia, especially those who do not respond to oral medication on a daily basis and do not adapt well to depot drugs. One of the results favouring penfluridol was a lower drop out rate in medium term when compared to depot medications. It is also an option for chronic sufferers of schizophrenia with residual psychotic symptoms who nevertheless need continuous use of antipsychotic medication. An additional benefit of penfluridol is that it is a low-cost intervention.</P>
<P>Note: the eight citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-11-07 12:16:36 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Schizophrenia is a serious, disabling, enduring and relapsing mental illness, the onset of which frequently occurs relatively early in life. It can result in a person experiencing problems with the ability to think, feel and perceive things clearly (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>). The worldwide lifetime prevalence of the disorder is about 1% (<LINK REF="REF-Torrey-1987" TYPE="REFERENCE">Torrey 1987</LINK>, <LINK REF="REF-Almeida_x002d_Filho-1997" TYPE="REFERENCE">Almeida-Filho 1997</LINK>).</P>
<P>One cause of relapse and readmission to hospital is poor compliance with antipsychotic medication often due to its adverse effects. Schizophrenia may also affect a person's insight, interfering with their ability to appreciate the benefit of taking medication long term. The relapse rate is significantly higher in those who have discontinued antipsychotic medication<B> </B>(<LINK REF="STD-Gallant-1974" TYPE="STUDY">Gallant 1974</LINK>).<B> </B>Penfluridol is an oral antipsychotic which is reputed to give antipsychotic protection for one week. This could prove a favourable option for treating those who do not wish to take daily or depot medication (<LINK REF="STD-Gallant-1974" TYPE="STUDY">Gallant 1974</LINK>).</P>
<P>Technical background<BR/>It has been said that Penfluridol is the first truly long-acting oral antipsychotic agent for the treatment of acute psychosis (<LINK REF="STD-Van-Praag-1971" TYPE="STUDY">Van Praag 1971</LINK>), chronic schizophrenia (<LINK REF="STD-Ionescu-1983" TYPE="STUDY">Ionescu 1983</LINK>) and Tourette's syndrome (<LINK REF="REF-Shapiro-1983" TYPE="REFERENCE">Shapiro 1983</LINK>). First synthesised in 1968, it is a white micro-crystalline tertiary amine, only slightly soluble in water and belongs to the diphenylbutylpiperidines; pimozide also belongs to this group (<LINK REF="REF-Janssen-1970" TYPE="REFERENCE">Janssen 1970</LINK>). Penfluridol is absorbed from the gastrointestinal tract and deposited in fatty tissue from which it is slowly released, resulting in a prolonged duration of action with a half-life of 70 hours. It is primarily excreted unchanged in the faeces; however, some hepatic metabolism and enterohepatic recycling occur ( <LINK REF="REF-Janssen-1972" TYPE="REFERENCE">Janssen 1972</LINK>, <LINK REF="STD-Gerlach-1975" TYPE="STUDY">Gerlach 1975</LINK>). Penfluridol is characterised pharmacologically by the traditional neuroleptic properties: cataleptogenic effect, antagonism against apomorphine and amphetamine induced stereotypes and inhibition of controlled behaviour. It also has a relatively specific antidopaminergic effect via the blocking of the dopaminergic receptor membrane (<LINK REF="REF-Janssen-1970" TYPE="REFERENCE">Janssen 1970</LINK>, <LINK REF="REF-Janssen-1972" TYPE="REFERENCE">Janssen 1972</LINK>, <LINK REF="STD-Gerlach-1975" TYPE="STUDY">Gerlach 1975</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To examine the effects of penfluridol for schizophrenia and schizophrenia-like illnesses in comparison to placebo, other antipsychotic medication or no intervention.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-11-07 10:42:01 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-10-31 12:12:07 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>We included all relevant randomised controlled trials. Where a trial was described as 'double-blind', but it was implied that the study was randomised, we included the trial in a sensitivity analysis. If there was no substantive difference within primary outcomes (see 'types of outcome measures') when these 'implied randomisation' studies were added, then we included these in the final analysis. If there was a substantive difference, we only analysed clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi-randomised studies, such as those allocating by using alternate days of the week.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We included people with schizophrenia and non-affective serious/chronic mental illness, irrespective of criteria of diagnosis, sex, and length of illness.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. Penfluridol: any dose taken orally. <BR/>2. Placebo (or no intervention). <BR/>3. Typical antipsychotic drugs: any dose and mode or pattern of administration. Examples of such drugs are chlorpromazine and haloperidol. <BR/>4. Atypical antipsychotic drugs: any dose and mode or pattern of administration. Examples of such drugs are clozapine, olanzapine, quetiapine and risperidone.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-31 12:12:07 +0000" MODIFIED_BY="[Empty name]">
<P>As schizophrenia is often a life-long illness and penfluridol is used as an ongoing treatment, outcomes were grouped according to time periods: short-term (less than three months), medium-term (3-12 months) and long-term (more than one year). It is assumed that long-term outcomes will be particularly relevant for this review given the properties of penfluridol.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-31 12:10:06 +0000" MODIFIED_BY="[Empty name]">
<P>1. Death</P>
<P>1.1 Suicide<BR/>1.2 Natural causes</P>
<P>2. Service utilisation outcomes<BR/>2.1 Hospital admission</P>
<P>3. Global outcomes<BR/>3.1 Clinically significant response in global state - as defined by each of the studies</P>
<P>4. Mental state<BR/>4.1 Clinically significant response in mental state - as defined by each of the studies</P>
<P>5. Behaviour<BR/>5.1 Leaving the study early</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-10-31 12:11:04 +0000" MODIFIED_BY="[Empty name]">
<P>1. Service utilisation outcomes<BR/>1.1 Days in hospital</P>
<P>2. Global outcomes<BR/>2.1 Average score/change in global state</P>
<P>3. Mental state<BR/>3.1 Average score/change in mental state<BR/>3.2 Clinically significant response on negative symptoms - as defined by each of the studies<BR/>3.3 Average score/change in negative symptoms<BR/>3.4 Relapse as defined in the study</P>
<P>4. Behaviour<BR/>4.1 Clinically significant response in behaviour - as defined by each of the studies<BR/>4.2 Average score/change in behaviour</P>
<P>5. Extrapyramidal side effects<BR/>5.1 Incidence of use of antiparkinson drugs<BR/>5.2 Clinically significant extrapyramidal side effects- as defined by each of the studies<BR/>5.3 Average score/change in extrapyramidal side effects</P>
<P>6. Other adverse effects, general and specific<BR/>6.1 Number of people dropping out due to adverse effects<BR/>6.2 Cardiac effects<BR/>6.3 Anticholinergic effects<BR/>6.4 Antihistamine effects<BR/>6.5 Prolactin related symptoms</P>
<P>7. Social functioning<BR/>7.1 Clinically significant response in social functioning - as defined by each of the studies<BR/>7.2 Average score/change in social functioning</P>
<P>8. Economic outcomes</P>
<P>9. Quality of life/satisfaction with care for either recipients of care or carers<BR/>9.1 Significant change in quality of life/satisfaction - as defined by each of the studies<BR/>9.2 Average score/change in quality of life/satisfaction<BR/>9.3 Employment status</P>
<P>10. Cognitive functioning</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-11-07 10:42:01 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2012-11-07 10:42:01 +0000" MODIFIED_BY="[Empty name]">
<P>1. We identified relevant randomised trials by searching the following electronic databases:</P>
<P>1.1. We searched the Cochrane Schizophrenia Group Trials Register (November 2005 and September 2000) using the phrase: [penfluridol* or micefal* or semap* or flupidol* in REFERENCE and penfluridol* or micefal* or semap* or flupidol* in STUDY)]</P>
<P>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see Group Module).</P>
<P>1.2. We searched LILACS (January 1982 to October 2005) using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and for schizophrenia (see Group search strategy) combined with: [AND (penfluridol or semap or penflu)]</P>
<P>1.3. We searched Cochrane Central Register of Controlled Trials (2003-5) using the phrase: [penfluridol or micefal or semap or flupidol] associated to the Cochrane Schizophrenia Group's phrase for schizophrenia.</P>
<P>1.4 Cochrane Schizophrenia Group Trials Register (September 2012)<B> </B>
</P>
<P>The Trials Search Co-ordinator searched the Cochrane Schizophrenia Group&#8217;s Trials Register</P>
<P>1.1 Title, Abstract and indexing terms search</P>
<P>These fields will be searched using the phrase:</P>
<P>*penfluridol* or *micefal* or *semap* or *flupidol* or *cyperon*</P>
<P>1.2 Intervention search</P>
<P>The &#8216;health care condition&#8217; field will be searched using the phrase:</P>
<P>*penfluridol* or *micefal* or *semap* or *flupidol* or *cyperon*</P>
<P>The Cochrane Schizophrenia Group&#8217;s Trials Register is compiled by systematic searches of major databases, handsearches of journals and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>). Incoming trials are assigned to relevant existing or new review titles.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-10-31 12:11:45 +0000" MODIFIED_BY="[Empty name]">
<P>1. Reference searching<BR/>We inspected the references of all identified studies for more trials. SCISEARCH (Science Citation Index (1974 to September 2000)) was used to trace papers that had cited included trials. We inspected these reports in order to identify further studies.</P>
<P>2. Personal contact<BR/>We contacted the first author of each included study for information regarding unpublished trials.</P>
<P>3. Pharmaceutical companies<BR/>We contacted the manufacturer of penfluridol (Jansen-Cilag Ltd) for additional data.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>1. Selection of trials <BR/>We inspected all reports (BGOS and CJSR) and MSL re-inspected a 10% sub-sample in order to ensure reliable selection. Where agreement could not be reached, we acquired the full report for more detailed scrutiny. Once the full articles were obtained we (BGOS and CJSR) decided whether they met the review criteria. MSL was sent 10% of all acquired articles to help promote reliability at this stage. Again, if disagreement could not be resolved from published information, we added the trial to those awaiting assessment and contacted the authors for further clarification.</P>
<P>2. Assessment of methodological quality <BR/>We assessed the methodological quality of trials included in this review using the criteria described in the Cochrane Handbook (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>) which is based on evidence of a strong relationship between allocation concealment and the potential for bias in the results. The categories are defined below: </P>
<P>A. Low risk of bias (adequate allocation concealment) <BR/>B. Moderate risk of bias (some doubt about the results) <BR/>C. High risk of bias (inadequate allocation concealment) </P>
<P>For the purpose of the analysis in this review, we included trials if they met the criteria A or B.</P>
<P>3. Data collection <BR/>We (CJSR with BGOS) independently extracted data from selected trials and MSL re-extracted information from a sample of 20%. When disputes arose, resolution was attempted by discussion. If this was not possible and further information was necessary to resolve the dilemma, we did not enter the data. </P>
<P>4. Data synthesis <BR/>4.1 Incomplete data <BR/>With the exception of the outcome of leaving the study early, we did not include trial outcomes if more than 50% of people were not reported in the final analysis.</P>
<P>4.2 Dichotomous data <BR/>We used an intention to treat analysis, on the condition that more than 50% of people completed the study and everyone allocated to the intervention was counted regardless of whether they completed the follow up. We assumed that those leaving the study early had the negative outcome, with the exception of death. We calculated the Relative risk (RR) and their 95% confidence interval (CI) based on the random effects model. This takes into account any differences between studies even if there is no statistically significant heterogeneity. We inspected the data to see if analysis using a fixed effects model made any substantive difference. Where possible we estimated the number needed to treat (NNT). </P>
<P>4.3 Continuous data<BR/>4.3.1 Normal data: data on continuous outcomes are frequently skewed, the mean not being the centre of the distribution. The statistics for meta-analysis are thought to be able to cope with some skew, but were formulated for parametric data. To avoid this potential pitfall, we applied the following standards to all data before inclusion: (a) standard deviations and means were reported or obtained from authors, (b) for data with finite limits, such as endpoint scale data, the standard deviation (SD), when multiplied by two, was less than the mean. Otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). We reported data that did not meet the first or second standard in 'other data' tables. </P>
<P>For change data (endpoint minus baseline), the situation is even more problematic. In the absence of individual patient data it is impossible to know if data are skewed, though this is likely to be the case. As carried out in other CSG reviews, we presented change data in MetaView in order to summarise available information. In doing this, it was assumed either that data were not skewed or that the analyses could cope with the unknown degree of skewness. Without individual patient data it is impossible to test this assumption. Where both change and endpoint data were available for the same outcome category, we only presented endpoint data. We acknowledge that by doing this much of the published change data were excluded, but argue that endpoint data is more clinically relevant and that if change data were to be presented along with endpoint data it would be given undeserved equal prominence. Authors of studies reporting only change data are being contacted for endpoint figures. We reported non-normally distributed data in the 'Other data types' tables. </P>
<P>4.3.2 Rating scales: a wide range of instruments are available to measure mental health outcomes. These instruments vary in quality and many are not valid,<B> </B>or even ad hoc. For outcome instruments some minimum standards have to be set. These were that: (a) the psychometric properties of the instrument should have been described in a peer-reviewed journal, (b) the instrument should either be: (i) a self-report, or (ii) completed by an independent rater or relative (not the therapist) and (c) the instrument should be a global assessment of an area of functioning (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>).</P>
<P>4.3.3 Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). </P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation co-efficient (ICC) [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>4.4 Sensitivity analyses <BR/>4.4.1 Dose: results for high doses (however 'high' was defined in the study), or &gt;60 mg/day if not defined, were compared to those for lower doses. <BR/>4.4.2 Treatment resistance: results from those whose illnesses were described as 'treatment resistant' were compared to those whose illnesses were not designated as such. <BR/>4.4.3 First episode: results from those experiencing their first episode of schizophrenia were compared to those with illness of longer duration.<BR/>4.4.4 The assumption of negative outcome: the primary outcome analysis employing the assumption of negative outcome for those who left early was compared to an analysis where complete data only were analysed.</P>
<P>5. Heterogeneity<BR/>Firstly, we undertook consideration of all the included studies within any comparison to estimate clinical heterogeneity. Then we used visual inspection of graphs to investigate the possibility of statistical heterogeneity. This was supplemented employing, primarily, the I-squared statistic. This provides an estimate of the percentage of inconsistency thought to be due to chance. Where the I-squared estimate was greater than or equal to 75% this was interpreted as evidence of high levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We did not summate data with 75% or greater I-squared statistic, but we presented these separately and investigated reasons for heterogeneity.</P>
<P>6. Addressing publication bias <BR/>Data from all identified and selected trials were entered into a funnel graph (trial effect versus trial size) in an attempt to investigate the likelihood of overt publication bias.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-11-07 12:16:36 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-11-07 12:16:36 +0000" MODIFIED_BY="[Empty name]">
<P>1. Excluded studies<BR/>We excluded 25 studies. Eleven were case series including only penfluridol (<LINK REF="STD-Bobon-1970" TYPE="STUDY">Bobon 1970</LINK>, <LINK REF="STD-Floru-1973" TYPE="STUDY">Floru 1973</LINK>, <LINK REF="STD-Glatzel-1973" TYPE="STUDY">Glatzel 1973</LINK>, <LINK REF="STD-Hasse-1971" TYPE="STUDY">Hasse 1971</LINK>, <LINK REF="STD-Kingstone-1977" TYPE="STUDY">Kingstone 1977</LINK>, <LINK REF="STD-Morales-1981" TYPE="STUDY">Morales 1981</LINK>, <LINK REF="STD-Richards-1976" TYPE="STUDY">Richards 1976</LINK>, <LINK REF="STD-Sharma-1988" TYPE="STUDY">Sharma 1988</LINK>, <LINK REF="STD-Shopsin-1977" TYPE="STUDY">Shopsin 1977</LINK>, <LINK REF="STD-Vaidyalingam-1990" TYPE="STUDY">Vaidyalingam 1990</LINK>, <LINK REF="STD-Woggon-1978" TYPE="STUDY">Woggon 1978</LINK>); twelve were not described as randomised, did not have information on allocation procedure, or did not present usable clinical data (<LINK REF="STD-Abuzzahab-1977" TYPE="STUDY">Abuzzahab 1977</LINK>, <LINK REF="STD-Angst-1975" TYPE="STUDY">Angst 1975</LINK>, <LINK REF="STD-Bao-1988" TYPE="STUDY">Bao 1988</LINK>, <LINK REF="STD-Baro-1972" TYPE="STUDY">Baro 1972</LINK>, <LINK REF="STD-Chouinard-1977" TYPE="STUDY">Chouinard 1977</LINK>, <LINK REF="STD-Cooper-1975" TYPE="STUDY">Cooper 1975</LINK>, <LINK REF="STD-Eklund-1976" TYPE="STUDY">Eklund 1976</LINK>, <LINK REF="STD-Floru-1975" TYPE="STUDY">Floru 1975</LINK>, <LINK REF="STD-Gallant-1975" TYPE="STUDY">Gallant 1975</LINK>, <LINK REF="STD-Nistico-1974" TYPE="STUDY">Nistico 1974</LINK>, <LINK REF="STD-Tanghe-1972" TYPE="STUDY">Tanghe 1972</LINK>, <LINK REF="STD-Van-Lommel-1974" TYPE="STUDY">Van Lommel 1974</LINK>).Two randomised controlled trials (<LINK REF="STD-Li-1987" TYPE="STUDY">Li 1987</LINK>, <LINK REF="STD-Linden-1973" TYPE="STUDY">Linden 1973</LINK>) did not present usable clinical outcomes.</P>
<P>2. Awaiting assessment<BR/>Twelve studies are awaiting assessment (<LINK REF="STD-Baro-1972a" TYPE="STUDY">Baro 1972a</LINK>, <LINK REF="STD-Duval-2006" TYPE="STUDY">Duval 2006</LINK>, <LINK REF="STD-Itoh-1976" TYPE="STUDY">Itoh 1976</LINK>, <LINK REF="STD-Jiang-1995" TYPE="STUDY">Jiang 1995</LINK>, <LINK REF="STD-Jus-1976" TYPE="STUDY">Jus 1976</LINK>, <LINK REF="STD-Kondo-1975" TYPE="STUDY">Kondo 1975</LINK>, <LINK REF="STD-Shu-1983" TYPE="STUDY">Shu 1983</LINK>, <LINK REF="STD-Strous-2007" TYPE="STUDY">Strous 2007</LINK>, <LINK REF="STD-Xun-2006" TYPE="STUDY">Xun 2006</LINK>, <LINK REF="STD-_x0e1b__x0e23__x0e35__x0e0a__x0e32_-2533" TYPE="STUDY">&#3611;&#3619;&#3637;&#3594;&#3634; 2533</LINK>, <LINK REF="STD-_x5b59__x8f7b__x9a91_-2007" TYPE="STUDY">&#23385;&#36731;&#39569; 2007</LINK>)</P>
<P>3. Ongoing<BR/>We are not aware of any ongoing studies.</P>
<P>4. Included Studies<BR/>We included 27 studies in this review. It is peculiar that 82% (22 studies) were published in the 70s, when the drug was launched, and the remaining five studies were published in the 1980s. Most trial centres were based in North America (seven in USA, and five in Canada), nine studies in Europe (four in Netherlands, two in Sweden, one in Romania, one in Belgium, and one in Denmark), three in India, one in Israel, one in New Zealand and one in Australia.</P>
<P>4.1 Lengths of Trials<BR/>Duration of studies varied widely, from 3 to 52 weeks. Five trials (<LINK REF="STD-Chouinard-1976" TYPE="STUDY">Chouinard 1976</LINK>, <LINK REF="STD-D_x0027_Elia-1977" TYPE="STUDY">D'Elia 1977</LINK>, <LINK REF="STD-Jacobsson-1976" TYPE="STUDY">Jacobsson 1976</LINK>, <LINK REF="STD-Munitz-1986" TYPE="STUDY">Munitz 1986</LINK>, <LINK REF="STD-Van-Praag-1971" TYPE="STUDY">Van Praag 1971</LINK>) were classified as short term studies (less than three months). The remaining twenty two were medium term trials (three months to one year), out of which nine lasted exactly three months. There were no long term trials (more than one year).</P>
<P>4.2 Participants<BR/>A total of 1024 people participated in the 27 trials with sample sizes ranging from 15 to 60 (mean 37.9). Fifty-two percent of studies had 40 or fewer participants. Standardised diagnostic criteria were described in only nine trials (DSM-II, DSM-III, RDC) though it is possible that people in the other trials had a clinical diagnosis of schizophrenia. Many studies (n=19) involved only people with chronic illness. The remaining studies included acutely ill and first episode participants; one in particular specified people with acute psychosis (<LINK REF="STD-Van-Praag-1971" TYPE="STUDY">Van Praag 1971</LINK>). Only one study (<LINK REF="STD-Zwanikken-1973" TYPE="STUDY">Zwanikken 1973</LINK>) included participants who had schizophrenia (n=17) and mental retardation (n=20). From the 21 studies which provided information on gender distribution there were 495 males and 269 females. Ages ranged from 17 to 70 years (mean from 18 studies was about 39.2 years). None of the studies focused on a specific age group.</P>
<P>4.3 Setting<BR/>Seventeen studies had inpatient setting (<LINK REF="STD-Baro-1970" TYPE="STUDY">Baro 1970</LINK>, <LINK REF="STD-Charalampous-1977" TYPE="STUDY">Charalampous 1977</LINK>, <LINK REF="STD-Chouinard-1976" TYPE="STUDY">Chouinard 1976</LINK>, <LINK REF="STD-D_x0027_Elia-1977" TYPE="STUDY">D'Elia 1977</LINK>, <LINK REF="STD-Deutsch-1976" TYPE="STUDY">Deutsch 1976</LINK>, <LINK REF="STD-Gallant-1974" TYPE="STUDY">Gallant 1974</LINK>, <LINK REF="STD-Jacobsson-1976" TYPE="STUDY">Jacobsson 1976</LINK>, <LINK REF="STD-James-1977" TYPE="STUDY">James 1977</LINK>, <LINK REF="STD-Jus-1974" TYPE="STUDY">Jus 1974</LINK>, <LINK REF="STD-Lapierre-1978" TYPE="STUDY">Lapierre 1978</LINK>, <LINK REF="STD-Munitz-1986" TYPE="STUDY">Munitz 1986</LINK>, <LINK REF="STD-Ota-1974" TYPE="STUDY">Ota 1974</LINK>, <LINK REF="STD-Quitkin-1977" TYPE="STUDY">Quitkin 1977</LINK>, <LINK REF="STD-Roelofs-1974" TYPE="STUDY">Roelofs 1974</LINK>, <LINK REF="STD-Vandecasteele-1974" TYPE="STUDY">Vandecasteele 1974</LINK>, <LINK REF="STD-Van-Praag-1971" TYPE="STUDY">Van Praag 1971</LINK> and <LINK REF="STD-Zwanikken-1973" TYPE="STUDY">Zwanikken 1973</LINK>). Four included only those who were not in hospital (<LINK REF="STD-Claghorn-1979" TYPE="STUDY">Claghorn 1979</LINK>, <LINK REF="STD-Donlon-1978" TYPE="STUDY">Donlon 1978</LINK>, <LINK REF="STD-Iqbal-1978" TYPE="STUDY">Iqbal 1978</LINK> and <LINK REF="STD-Kurland-1975" TYPE="STUDY">Kurland 1975</LINK>). Two studies included inpatients and outpatients (<LINK REF="STD-Gerlach-1975" TYPE="STUDY">Gerlach 1975</LINK>, <LINK REF="STD-Ionescu-1983" TYPE="STUDY">Ionescu 1983</LINK>). The setting was unclear in four of the included trials (<LINK REF="STD-Channabasavanna-1987" TYPE="STUDY">Channabasavanna 1987</LINK>, <LINK REF="STD-Doongaji-1988" TYPE="STUDY">Doongaji 1988</LINK>, <LINK REF="STD-Khorana-1988" TYPE="STUDY">Khorana 1988</LINK>, <LINK REF="STD-Wang-1982" TYPE="STUDY">Wang 1982</LINK>).</P>
<P>4.4 Interventions<BR/>The mean dose of penfluridol, based on 13 studies which reported it<B> </B>was about 39 mg/week and the range, taken from 18 studies, was 5 to 160 mg/week. In <LINK REF="STD-Munitz-1986" TYPE="STUDY">Munitz 1986</LINK> participants allocated to placebo received one dose of penfluridol 20 mg on the first day post-randomisation. This study was included in order to increase the applicability of the data (such inclusion did not change the overall findings). Ten studies compared penfluridol to placebo (<LINK REF="STD-Baro-1970" TYPE="STUDY">Baro 1970</LINK>, <LINK REF="STD-Channabasavanna-1987" TYPE="STUDY">Channabasavanna 1987</LINK>, <LINK REF="STD-Deutsch-1976" TYPE="STUDY">Deutsch 1976</LINK>, <LINK REF="STD-Gallant-1974" TYPE="STUDY">Gallant 1974</LINK>, <LINK REF="STD-Kurland-1975" TYPE="STUDY">Kurland 1975</LINK>, <LINK REF="STD-Munitz-1986" TYPE="STUDY">Munitz 1986</LINK>, <LINK REF="STD-Roelofs-1974" TYPE="STUDY">Roelofs 1974</LINK>, <LINK REF="STD-Vandecasteele-1974" TYPE="STUDY">Vandecasteele 1974</LINK>, <LINK REF="STD-Van-Praag-1971" TYPE="STUDY">Van Praag 1971</LINK>, <LINK REF="STD-Zwanikken-1973" TYPE="STUDY">Zwanikken 1973</LINK>). Ten studies (<LINK REF="STD-Charalampous-1977" TYPE="STUDY">Charalampous 1977</LINK>, <LINK REF="STD-Chouinard-1976" TYPE="STUDY">Chouinard 1976</LINK>, <LINK REF="STD-Claghorn-1979" TYPE="STUDY">Claghorn 1979</LINK>, <LINK REF="STD-D_x0027_Elia-1977" TYPE="STUDY">D'Elia 1977</LINK>, <LINK REF="STD-Donlon-1978" TYPE="STUDY">Donlon 1978</LINK>, <LINK REF="STD-Jacobsson-1976" TYPE="STUDY">Jacobsson 1976</LINK>, <LINK REF="STD-Jus-1974" TYPE="STUDY">Jus 1974</LINK>, <LINK REF="STD-Khorana-1988" TYPE="STUDY">Khorana 1988</LINK>, <LINK REF="STD-Lapierre-1978" TYPE="STUDY">Lapierre 1978</LINK>, <LINK REF="STD-Wang-1982" TYPE="STUDY">Wang 1982</LINK>) compared penfluridol with typical oral antipsychotics such as fluphenazine or chlorpromazine. Six studies (<LINK REF="STD-Doongaji-1988" TYPE="STUDY">Doongaji 1988</LINK>, <LINK REF="STD-Gerlach-1975" TYPE="STUDY">Gerlach 1975</LINK>, <LINK REF="STD-Ionescu-1983" TYPE="STUDY">Ionescu 1983</LINK>, <LINK REF="STD-Iqbal-1978" TYPE="STUDY">Iqbal 1978</LINK>, <LINK REF="STD-James-1977" TYPE="STUDY">James 1977</LINK>, <LINK REF="STD-Quitkin-1977" TYPE="STUDY">Quitkin 1977</LINK>) compared penfluridol with depot antipsychotics such as fluphenazine decanoate or flupenthixol decanoate, and one study (<LINK REF="STD-Ota-1974" TYPE="STUDY">Ota 1974</LINK>) compared penfluridol to the previously used antipsychotics (without naming them). None of the trials compared penfluridol with an atypical antipsychotic.</P>
<P>4.5 Outcomes<BR/>Most outcomes were reported as dichotomous (yes-no/ binary outcomes) and were presented as such. Most scale derived data were unusable as they were usually presented as a graph or as mean without standard deviation or standard error. The main efficacy outcome, described as 'no marked improvement', was derived from Clinical Global Impression (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>), dichotomised in 'no improvement or worse'. Two studies (<LINK REF="STD-Ionescu-1983" TYPE="STUDY">Ionescu 1983</LINK> and <LINK REF="STD-Lapierre-1978" TYPE="STUDY">Lapierre 1978</LINK>) presented data from mental state as BPRS, with mean and standard deviation. Included studies did not present any data on economic outcomes.</P>
<P>4.5.1 Scales presented in analysis<BR/>4.5.1.1. Global state<BR/>4.5.1.1.1 Clinical Global Impression - CGI (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>A rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. A seven point scoring system is usually used with low scores indicating decreased severity and/or greater recovery. Usable data from this scale was reported by <LINK REF="STD-Charalampous-1977" TYPE="STUDY">Charalampous 1977</LINK>, <LINK REF="STD-Deutsch-1976" TYPE="STUDY">Deutsch 1976</LINK>, <LINK REF="STD-Donlon-1978" TYPE="STUDY">Donlon 1978</LINK>, <LINK REF="STD-Gallant-1974" TYPE="STUDY">Gallant 1974</LINK>, <LINK REF="STD-Gerlach-1975" TYPE="STUDY">Gerlach 1975</LINK>, <LINK REF="STD-Ionescu-1983" TYPE="STUDY">Ionescu 1983</LINK> and <LINK REF="STD-Kurland-1975" TYPE="STUDY">Kurland 1975</LINK>.</P>
<P>4.5.2. Mental state<BR/>4.5.2.1. Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1961" TYPE="REFERENCE">Overall 1961</LINK>)<BR/>A brief rating scale used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The original scale has 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven-point scale varying from 'not present' to 'extremely severe', scoring from 0-6 or 1-7. Scores can range from 0-126, with high scores indicating more severe symptoms. Usable data from this scale was reported by <LINK REF="STD-Ionescu-1983" TYPE="STUDY">Ionescu 1983</LINK> and <LINK REF="STD-Lapierre-1978" TYPE="STUDY">Lapierre 1978</LINK>.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>1. Randomisation<BR/>Two studies (<LINK REF="STD-Munitz-1986" TYPE="STUDY">Munitz 1986</LINK>, <LINK REF="STD-Lapierre-1978" TYPE="STUDY">Lapierre 1978</LINK>) described adequate methods of allocation concealment. In <LINK REF="STD-Munitz-1986" TYPE="STUDY">Munitz 1986</LINK>, participants were recruited in the emergency unit by a physician who did not take part in the study. Nursing staff recorded the random numbers and administered the medication. The treatment physician was blind to the assignment. <LINK REF="STD-Lapierre-1978" TYPE="STUDY">Lapierre 1978</LINK> gave a detailed description of the allocation procedure that could be summarised as: medication packaged and numbered with random numbers, sealed bottles and sealed envelopes. In reply to our request, Dr Simpson (<LINK REF="STD-Iqbal-1978" TYPE="STUDY">Iqbal 1978</LINK>), confirmed that there was allocation concealment, but did not give further information. These three studies were given the quality score 'A'. The remaining 24 studies were classified as 'B', regarding the allocation concealment. Nineteen studies were described as randomised; two studies (<LINK REF="STD-Roelofs-1974" TYPE="STUDY">Roelofs 1974</LINK> and <LINK REF="STD-Vandecasteele-1974" TYPE="STUDY">Vandecasteele 1974</LINK>) had the allocation done by an 'unbiased statistician' without further details. Three studies (<LINK REF="STD-D_x0027_Elia-1977" TYPE="STUDY">D'Elia 1977</LINK>, <LINK REF="STD-Ionescu-1983" TYPE="STUDY">Ionescu 1983</LINK>, <LINK REF="STD-Jacobsson-1976" TYPE="STUDY">Jacobsson 1976</LINK>) with unclear allocation procedure were included after a sensitivity analysis (there were no substantive differences within primary outcomes).<BR/> <BR/>2. Blinding<BR/>All included trials used a double blind design, except for <LINK REF="STD-D_x0027_Elia-1977" TYPE="STUDY">D'Elia 1977</LINK>, <LINK REF="STD-Ionescu-1983" TYPE="STUDY">Ionescu 1983</LINK>, <LINK REF="STD-Ota-1974" TYPE="STUDY">Ota 1974</LINK>, which were open studies. Seven studies (<LINK REF="STD-Channabasavanna-1987" TYPE="STUDY">Channabasavanna 1987</LINK>, <LINK REF="STD-Claghorn-1979" TYPE="STUDY">Claghorn 1979</LINK>, <LINK REF="STD-Donlon-1978" TYPE="STUDY">Donlon 1978</LINK>, <LINK REF="STD-Doongaji-1988" TYPE="STUDY">Doongaji 1988</LINK>, <LINK REF="STD-Jus-1974" TYPE="STUDY">Jus 1974</LINK>, <LINK REF="STD-Khorana-1988" TYPE="STUDY">Khorana 1988</LINK>, <LINK REF="STD-Wang-1982" TYPE="STUDY">Wang 1982</LINK>) also described forms of blinding, such as use of identical capsules.</P>
<P>3. Leaving the study early<BR/>Eighteen studies reported participants leaving the study early. Reasons for leaving early were only described by <LINK REF="STD-Iqbal-1978" TYPE="STUDY">Iqbal 1978</LINK>.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>1. The search <BR/>The electronic databases search identified 54 references, reference cross-checking provided ten citations, contact with a pharmaceutical company (Jansen) provided a further six, and contacting authors of included studies has not yielded further studies. Twenty seven studies are included in this review, 25 are described as excluded, and four are awaiting assessment. </P>
<P>2. COMPARISON 1. PENFLURIDOL versus PLACEBO<BR/>Ten studies allocated 305 people to this comparison.</P>
<P>2.1 Global state: 1. no marked improvement (CGI)<BR/>Four medium-term studies presented results for change in global state (<LINK REF="STD-Deutsch-1976" TYPE="STUDY">Deutsch 1976</LINK>, <LINK REF="STD-Gallant-1974" TYPE="STUDY">Gallant 1974</LINK>, Kurland 1975, <LINK REF="STD-Zwanikken-1973" TYPE="STUDY">Zwanikken 1973</LINK>), and pooled data favoured penfluridol (n=159, RR 0.69 CI 0.6 to 0.8, NNT 4 CI 3 to 8).</P>
<P>2.2 Global state: 2. needing additional antipsychotic<BR/>Subjects taking penfluridol needed less additional antipsychotics than those taking placebo, either in one short-term study (<LINK REF="STD-Van-Praag-1971" TYPE="STUDY">Van Praag 1971</LINK>, n=34, RR 0.45 CI 0.2 to 0.9, NNT 2 CI 1 to 7), or with the pooled data from five medium-term studies (<LINK REF="STD-Channabasavanna-1987" TYPE="STUDY">Channabasavanna 1987</LINK>, Kurland 1975, <LINK REF="STD-Roelofs-1974" TYPE="STUDY">Roelofs 1974</LINK>, <LINK REF="STD-Vandecasteele-1974" TYPE="STUDY">Vandecasteele 1974</LINK>, <LINK REF="STD-Zwanikken-1973" TYPE="STUDY">Zwanikken 1973</LINK>, n=138, RR 0.43 CI 0.2 to 0.8, NNT 3 CI 2 to 20).</P>
<P>2.3 Leaving the study early<BR/>One short-term (<LINK REF="STD-Van-Praag-1971" TYPE="STUDY">Van Praag 1971</LINK>) presented result for this data, with no differences between interventions. Three medium-term studies evaluated this outcome. <LINK REF="STD-Baro-1970" TYPE="STUDY">Baro 1970</LINK> and Kurland 1975 favoured penfluridol, and <LINK REF="STD-Channabasavanna-1987" TYPE="STUDY">Channabasavanna 1987</LINK> did not show differences between penfluridol and placebo. Pooled data of these three studies favoured penfluridol (n=91, RR 0.13, CI 0.02 to 0.9).</P>
<P>2.4. Adverse events: 1. Extrapyramidal<BR/>Extrapyramidal adverse effects were reported in only two studies, and the meta-analysis of these trials was equivocal. Medium term data from <LINK REF="STD-Gallant-1974" TYPE="STUDY">Gallant 1974</LINK> were significant (n=50, RR 5.33 CI 1.8 to 16.1), while <LINK REF="STD-Munitz-1986" TYPE="STUDY">Munitz 1986</LINK> short term data were found to be equivocal (n=20, RR of 0.50 CI 0.1 to 4.7).</P>
<P>2.5. Adverse events: 2. Other side effects<BR/>Two medium-term studies (<LINK REF="STD-Channabasavanna-1987" TYPE="STUDY">Channabasavanna 1987</LINK>, <LINK REF="STD-Vandecasteele-1974" TYPE="STUDY">Vandecasteele 1974</LINK>) evaluated the need for antiparkinson medication and reported no difference between penfluridol and placebo (n=51, RR 1.04 CI 0.6 to 1.9). <LINK REF="STD-Gallant-1974" TYPE="STUDY">Gallant 1974</LINK> referred a higher incidence of ECG alterations in those patients treated with penfluridol, but this difference was not statistically significant (n=50, RR 3.0 CI 0.7 to 13.5). <LINK REF="STD-Vandecasteele-1974" TYPE="STUDY">Vandecasteele 1974</LINK> reported equivocal results (n=21, RR of 2.73 CI 0.3 to 22.2) for insomnia when comparing penfluridol with placebo.</P>
<P>3. COMPARISON 2. PENFLURIDOL versus TYPICAL (ORAL) ANTIPSYCHOTIC<BR/>A total of 449 patients from 11 studies were randomised to this comparison. </P>
<P>3.1 Global state: 1. no marked improvement (CGI)<BR/>Two medium-term studies reported changes in global state (<LINK REF="STD-Charalampous-1977" TYPE="STUDY">Charalampous 1977</LINK>, <LINK REF="STD-Donlon-1978" TYPE="STUDY">Donlon 1978</LINK>). They found no statistically significant difference between interventions (n=80, RR 0.92 CI 0.7 to 1.2).</P>
<P>3.2 Global state: 2. needing additional antipsychotic<BR/>Two short-term studies (<LINK REF="STD-Chouinard-1976" TYPE="STUDY">Chouinard 1976</LINK>, <LINK REF="STD-Jacobsson-1976" TYPE="STUDY">Jacobsson 1976</LINK>) reported data on this outcome, with no statistically significant difference between penfluridol and other typical antipsychotics (n=90, RR 1.35 CI 0.9 to 2.0). Regarding the need for additional antipsychotic medium-term studies, again, no statistical difference was observed (n=105, RR 1.08 CI 0.7 to 1.8). The studies were <LINK REF="STD-Donlon-1978" TYPE="STUDY">Donlon 1978</LINK>, <LINK REF="STD-Jus-1974" TYPE="STUDY">Jus 1974</LINK> and <LINK REF="STD-Wang-1982" TYPE="STUDY">Wang 1982</LINK>. </P>
<P>3.3 Mental state: BPRS endpoint score<BR/>Only one study supplied continuous data which could be re-analysed for this comparison. We contacted study authors by letter, but only <LINK REF="STD-Lapierre-1978" TYPE="STUDY">Lapierre 1978</LINK> has supplied data from the BPRS scale with means and standard deviations from this one-year study. No statistically significant differences between penfluridol and fluphenazine were observed in endpoint scores (n=41, WMD 1.24 CI -4.4 to 6.9).</P>
<P>3.4 Leaving the study early<BR/>Three short-term studies (<LINK REF="STD-Chouinard-1976" TYPE="STUDY">Chouinard 1976</LINK>, <LINK REF="STD-Jacobsson-1976" TYPE="STUDY">Jacobsson 1976</LINK>, <LINK REF="STD-D_x0027_Elia-1977" TYPE="STUDY">D'Elia 1977</LINK>) reported data on this outcome, with no statistically significant difference between penfluridol and other typical antipsychotics (n=118, RR 0.46 CI 0.2 to 1.4). Six medium-term studies presented data regarding this comparison without specifying the reason for leaving the study early (<LINK REF="STD-Charalampous-1977" TYPE="STUDY">Charalampous 1977</LINK>, <LINK REF="STD-Claghorn-1979" TYPE="STUDY">Claghorn 1979</LINK>, <LINK REF="STD-Donlon-1978" TYPE="STUDY">Donlon 1978</LINK>, <LINK REF="STD-Lapierre-1978" TYPE="STUDY">Lapierre 1978</LINK>, <LINK REF="STD-Ota-1974" TYPE="STUDY">Ota 1974</LINK>, <LINK REF="STD-Wang-1982" TYPE="STUDY">Wang 1982</LINK>). Pooled data from these studies showed that people were no more likely to leave the study early with penfluridol or with oral typical antipsychotic (n=235, RR 1.16 CI 0.8 to 1.7). <BR/> <BR/>3.5 Adverse events: 1. needing antiparkinsonian medication<BR/>There were no differences between penfluridol and oral typical antipsychotics in the additional use of antiparkinsonian drugs, neither in two short-term studies (<LINK REF="STD-Chouinard-1976" TYPE="STUDY">Chouinard 1976</LINK>, <LINK REF="STD-Jacobsson-1976" TYPE="STUDY">Jacobsson 1976</LINK>, n=90, RR 1.09 CI 0.6 to 2.0), nor in three medium-term studies (<LINK REF="STD-Charalampous-1977" TYPE="STUDY">Charalampous 1977</LINK>, <LINK REF="STD-Khorana-1988" TYPE="STUDY">Khorana 1988</LINK>, <LINK REF="STD-Lapierre-1978" TYPE="STUDY">Lapierre 1978</LINK>, <LINK REF="STD-Wang-1982" TYPE="STUDY">Wang 1982</LINK>, n=169, RR 1.20 CI 0.9 to 1.6). </P>
<P>3.6 Adverse events: 2. Other side effects<BR/>There were no differences favouring penfluridol either in short or medium term treatment for the side effects: insomnia, akathisia, acute dystonia, lack of facial expression, drowsiness, nausea, fatigue, tremors, postural hypotension, rigidity and muscle span.</P>
<P>4. COMPARISON 3. PENFLURIDOL versus TYPICAL (DEPOT) ANTIPSYCHOTIC<BR/>A total of 274 patients from six studies were randomised to this comparison. </P>
<P>4.1 Global state: 1. no marked improvement (CGI)<BR/>Only one medium-term study (<LINK REF="STD-Ionescu-1983" TYPE="STUDY">Ionescu 1983</LINK>) reported data on this outcome, with no statistically significant difference between penfluridol and fluphenazine decanoate (n=60, RR 0.60 CI 0.2 to 2.3).</P>
<P>4.2 Global state: 2. needing additional antipsychotic<BR/>Two medium-term studies (<LINK REF="STD-Ionescu-1983" TYPE="STUDY">Ionescu 1983</LINK> and <LINK REF="STD-Iqbal-1978" TYPE="STUDY">Iqbal 1978</LINK>) showed equivocal findings (n=98, RR 0.67 CI 0.2 to 1.9).</P>
<P>4.3 Mental state - BPRS<BR/>Only one medium-term study (<LINK REF="STD-Ionescu-1983" TYPE="STUDY">Ionescu 1983</LINK>) has supplied data from the BPRS scale with means and standard deviations. There was no statistically significant difference between penfluridol and fluphenazine decanoate (n=60, WMD -2.60 CI -5.5 to 0.3).</P>
<P>4.4 Leaving the study early <BR/>Data from five medium-term studies (<LINK REF="STD-Doongaji-1988" TYPE="STUDY">Doongaji 1988</LINK>, <LINK REF="STD-Gerlach-1975" TYPE="STUDY">Gerlach 1975</LINK>, <LINK REF="STD-Iqbal-1978" TYPE="STUDY">Iqbal 1978</LINK>, <LINK REF="STD-James-1977" TYPE="STUDY">James 1977</LINK>, <LINK REF="STD-Quitkin-1977" TYPE="STUDY">Quitkin 1977</LINK>) showed that more patients dropped out of the depot typical antipsychotics group than the penfluridol one (n=218, RR 0.55 CI 0.3 to 0.97, NNT 6 CI 3 to 50). In<B> </B>
<LINK REF="STD-Iqbal-1978" TYPE="STUDY">Iqbal 1978</LINK>
<B>, </B>one person was categorised as 'leaving the study early' due to attempted suicide in the penfluridol group. In this same trial no-one in the penfluridol group left the study early due to side-effects.</P>
<P>4.5 Adverse events: 1. needing antiparkinsonian medication<BR/>Data pooled from three medium-term studies (<LINK REF="STD-Ionescu-1983" TYPE="STUDY">Ionescu 1983</LINK>, <LINK REF="STD-Iqbal-1978" TYPE="STUDY">Iqbal 1978</LINK> and <LINK REF="STD-James-1977" TYPE="STUDY">James 1977</LINK>) did not show a difference between groups for this outcome (n=114, RR 0.87 CI 0.7 to 1.0).</P>
<P>4.6 Adverse events: other side effects<BR/>Several adverse effects were described in two trials, with no statistically significant differences between interventions for insomnia, akathisia, rigidity, lack of facial expression, difficulty with visual accommodation, hypersalivation, fatigue, tremors and lethargy.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>1. General<BR/>This systematic review is retrospective research and, after an exhaustive search for studies, it was possible to include in the analysis almost all publications of controlled clinical trials in which penfluridol was compared to placebo or to other antipsychotics. We found 27 relevant studies, but data are limited due to small sample sizes and poor reporting of outcomes. This may be partially explained because most of the trials were published in the 1970s, when there were no clear concerns and guidance for conducting trials were not yet published (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>). Moreover, many outcomes could not be re-analysed with the conservative inclusion and methodological quality criteria that give strength to the Cochrane reviews. Information supplied by the study authors helped to improve the quality and reliability of this review.</P>
<P>The population of these primary studies may be peculiar in some aspects because most trials included patients that were hospitalised, with a long course of the disease, but excluded clinical co-morbidities that are common in people with schizophrenia.</P>
<P>2. PENFLURIDOL versus PLACEBO<BR/>Penfluridol was superior compared to placebo in the efficacy outcomes (global state, need for additional antipsychotics). Nevertheless, small sample sizes demands caution in the interpretation of these findings. If analysing the data from placebo controlled studies, penfluridol seems to be a drug that presents the same profile as other typical antipsychotics.</P>
<P>3. PENFLURIDOL versus TYPICAL ANTIPSYCHOTICS<BR/>When compared to other antipsychotics (oral and depot), penfluridol showed similar efficacy and tolerance. Penfluridol did not lead to excessive sedation and in general terms it was well tolerated. When penfluridol was compared to depot medications, it showed better results in terms of keeping the patients in treatment, providing lower dropout rates in medium-term (16.4% vs 31.5%, respectively, p=0.04, NNT 6). </P>
<P>4. Quality of reporting<BR/>Although only randomised and controlled clinical trials were included, 85% of them did not report the randomisation procedure for the participants. This implies that the quality of the randomised allocation process might have been affected. The trials were also limited due to small sample sizes and none of the included studies reported how the sample size was calculated.</P>
<P>All studies were carried out in the 1970s and 1980s, when methodological quality and the amount of data reported in the publications were generally poor. In the 1990s a number of papers highlighted the importance of detailing data, mainly data relating to methodology, quantity and quality of information published (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>, <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Scientific publications currently present stricter criteria for publishing clinical trials.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-11-07 10:47:29 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE>
<P>1. For people with schizophrenia<BR/>Penfluridol has shown to be an adequate treatment option for people with schizophrenia, especially for those who do not respond to oral medication on a daily basis and who do not adapt to depot drugs. It is also effective in treating those chronic patients with residual psychotic symptoms who nevertheless need continuous use of antipsychotic medication. Penfluridol is also attractive in terms of cost, since it is an affordable drug with a monthly cost (40 mg/week) of US $4 on the Brazilian market.</P>
<P>2. For managers or policy makers <BR/>Data relating to service utilisation, satisfaction with care and economic outcomes were not reported.</P>
<P>3. For clinicians <BR/>Penfluridol is a suitable therapeutic alternative. Its efficacy is similar to other typical antipsychotics, both oral and depot, and its adverse effects seem to be similar to those from butyrophenones. Based on the doses of penfluridol used in the studies included in this review (mean dose ~40 mg/ week from 13 studies), we suggest that a dose ranging from 40 to 80 mg/week may be enough to result in clinical improvement.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-11-07 10:47:29 +0000" MODIFIED_BY="[Empty name]">
<P>1. General<BR/>All trials reviewed predated the CONSORT statement (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>, <LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>). Had this been anticipated, possibly far more data would have been available to inform practice. Allocation concealment gives the assurance that selection bias is kept to a minimum and should be properly described. Only three studies in this review reported independent allocation or allocation concealment. For the other studies, we were given little assurance that bias was minimised during the allocation procedure. Well reported and tested blinding could have encouraged confidence in the control of performance and detection bias. Included trials used a double blind design, except for <LINK REF="STD-D_x0027_Elia-1977" TYPE="STUDY">D'Elia 1977</LINK>, <LINK REF="STD-Ionescu-1983" TYPE="STUDY">Ionescu 1983</LINK> and <LINK REF="STD-Ota-1974" TYPE="STUDY">Ota 1974</LINK>, which were open studies. Seven studies (<LINK REF="STD-Channabasavanna-1987" TYPE="STUDY">Channabasavanna 1987</LINK>, <LINK REF="STD-Claghorn-1979" TYPE="STUDY">Claghorn 1979</LINK>, <LINK REF="STD-Donlon-1978" TYPE="STUDY">Donlon 1978</LINK>, <LINK REF="STD-Doongaji-1988" TYPE="STUDY">Doongaji 1988</LINK>, <LINK REF="STD-Jus-1974" TYPE="STUDY">Jus 1974</LINK>, <LINK REF="STD-Khorana-1988" TYPE="STUDY">Khorana 1988</LINK>, <LINK REF="STD-Wang-1982" TYPE="STUDY">Wang 1982</LINK>) even described forms of blinding, such as use of identical capsules. It is also important to note how many, and from which groups, people were withdrawn in order to evaluate exclusion bias. Raters should be independent of treatment. Continuous data was poorly reported in the reviewed studies. It would have been helpful if study authors had presented data in a way which reflected associations between intervention and outcome, for example, relative risk, odds-ratio, risk or mean differences, as well as raw numbers. Binary outcomes should be calculated in preference to continuous results, as they are easier to interpret. If p-values are used, the exact value should be reported. Service utilisation data as well as satisfaction with care and economic outcomes should also be reported in trials.</P>
<P>2. Specific - is more research needed?<BR/>All studies in this review were carried out in the 1970s and 1980s, and the last clinical trial included in this review took place in 1988. New studies comparing penfluridol to both typical and atypical antipsychotics could be undertaken. More precise studies, with larger sample sizes, could better define efficacy and comparative tolerance of this drug.<BR/>
<BR/>3. Note: the eight citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Professor Clive Adams (Cochrane Schizophrenia Group, UK) gave invaluable help, advice and encouragement. </P>
<P>Professor Kristian Wahlbeck (lecturer, editor, University of Helsinki, Cochrane Schizophrenia Group, Finland) very kindly provided data and assessment of one Chinese study.</P>
<P>The reviewers would also like to warmly thank Tessa Grant and Gill Rizzello of the Cochrane Schizophrenia Group, UK for their invaluable support.</P>
<P>We also would like to thank doctors Lapierre, Munitz, Zwanikken, Simpson (<LINK REF="STD-Iqbal-1978" TYPE="STUDY">Iqbal 1978</LINK>) for replying to our letters.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Bernardo Soares and Mauricio Lima are employees of Eli Lilly Brazil.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Bernardo Soares - review writing, data collection, analysis, final report.</P>
<P>Maurício Lima - review writing, data collection, analysis, final report.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-11-07 10:45:36 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-11-07 10:45:36 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Baro-1970" NAME="Baro 1970" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baro F, Brugmans J, Dom R, van Lommel R</AU>
<TI>Maintenance therapy of chronic psychotic patients with a weekly oral dose of R 16 341. A controlled double-blind study</TI>
<SO>Journal of Clinical Pharmacology and the Journal of New Drugs</SO>
<YR>1970</YR>
<VL>10</VL>
<NO>5</NO>
<PG>330-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Channabasavanna-1987" NAME="Channabasavanna 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Channabasavanna SM, Micheal A</AU>
<TI>Penfluridol maintenance therapy in schizophrenia: a controlled study</TI>
<SO>Indian Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>29</VL>
<NO>4</NO>
<PG>333-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Charalampous-1977" NAME="Charalampous 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Charalampous K, Thornby J, Ford BK, Freemesser GF</AU>
<TI>Penfluridol versus oral fluphenazine in the maintenance treatment of chronic schizophrenics</TI>
<SO>Current Therapeutic Research</SO>
<YR>1977</YR>
<VL>21</VL>
<NO>2</NO>
<PG>215-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1976" NAME="Chouinard 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Annablle L, Kolivakis TN</AU>
<TI>Penfluridol in the maintenance treatment of schizophrenic patients newly dicharged from a brief therapy unit</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1976</YR>
<VL>17</VL>
<NO>2-3</NO>
<PG>162-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Annablle L</AU>
<TI>Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1976</YR>
<VL>133</VL>
<NO>7</NO>
<PG>850-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Claghorn-1979" NAME="Claghorn 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Author unknow at the adress&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Claghorn JL, Mathew RJ, Mirabi M</AU>
<TI>Penfluridol: a long acting oral antipsychotic drug</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1979</YR>
<VL>40</VL>
<NO>2</NO>
<PG>107-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Elia-1977" NAME="D'Elia 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Carta enviada ao autor&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>d'Elia G, Jacobsson L, von Knorring L, Mattsson B, Mjorndal T, Oreland L, Perris C, Rapp W</AU>
<TI>Changes in psychopathology in relation to EEG variables and visual averaged evoked responses (V.AER) in schizophrenic patients treated with penfluridol or thiothixene</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1977</YR>
<VL>55</VL>
<PG>309-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deutsch-1976" NAME="Deutsch 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Author unknow at the adress&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deutsch M, Nair NPV, Saarma J</AU>
<TI>Penfluridol in the treatment of schizophrenia: clinical and psychometric findings</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1976</YR>
<VL>12</VL>
<NO>1</NO>
<PG>34-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donlon-1978" NAME="Donlon 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Author unknow at the adress&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donlon PT, Meyer JE</AU>
<TI>A twelve month comparison of penfluridol and trifluoperazine in chronic schizophrenic outpatients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1978</YR>
<VL>39</VL>
<NO>6</NO>
<PG>582-3,586-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doongaji-1988" NAME="Doongaji 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doongaji DR, Sheth AS, Apte JS, Desai AB, Gupta L</AU>
<TI>Penfluridol vs fluphenazine decanoate: a double blind clinical study in chronic and subchronic schizophrenia</TI>
<SO>Current Therapeutic Research</SO>
<YR>1988</YR>
<VL>43</VL>
<NO>3</NO>
<PG>416-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallant-1974" NAME="Gallant 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Author sent only a copy from the study&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallant DM, Mielke DH, Spirtes MA, Swanson WC, Bost R</AU>
<TI>Penfluridol: an efficacious long-acting oral antipsychotic compound</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1974</YR>
<VL>131</VL>
<PG>699-702</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerlach-1975" NAME="Gerlach 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerlach J, Kramp P, Kristjansen P, Lauritsen B, Luhdorf K, Munkvad I</AU>
<TI>Peroral and parenteral administration of long-acting neuroleptics: a double-blind study of penfluridol compared to flupenthixol decanoate in the treatment of schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1975</YR>
<VL>52</VL>
<NO>2</NO>
<PG>132-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ionescu-1983" NAME="Ionescu 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Allocation unclear. Sent letter to the author&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ionescu R, Tiberiu C, Miklos R, Angelescu C, Perciceanu AP</AU>
<TI>Penfluridol in the maintenance therapy of schizophrenia</TI>
<SO>Neurologie et Psychiatrie</SO>
<YR>1983</YR>
<VL>21</VL>
<NO>1</NO>
<PG>33-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iqbal-1978" NAME="Iqbal 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Allocation unclear. Sent letter to the author - Author answer by e-mail&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iqbal MJ, Young MA, Charles J, Elgart B, Von Greiff H, Simpson G</AU>
<TI>A long term comparative trial of penfluridol and fluphenazine decanoate in schizophrenic outpatients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1978</YR>
<VL>39</VL>
<NO>4</NO>
<PG>375-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobsson-1976" NAME="Jacobsson 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Allocation unclear. Sent letter to the author&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jacobsson L, Von Knorring L, Mattsson B, Perris C, Rapp W, Edenius B, Kettner B, Magnusson KE, Villemoes P</AU>
<TI>Controlled trial of penfluridol and thiothixene in the maintenance treatment of chronic schizophrenic syndromes</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1976</YR>
<VL>54</VL>
<NO>2</NO>
<PG>125-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacobsson L, Von Knorring L, Mattsson B, Perris C, Rapp W, Edenius B, Kettner B, Magnusson KE, Villemoes P</AU>
<TI>Penfluridol and thiothixene, dosage plasma levels and changes in psychopathology</TI>
<SO>International Pharmachopsychiatry</SO>
<YR>1976</YR>
<VL>11</VL>
<NO>4</NO>
<PG>206-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-James-1977" NAME="James 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>James NM, Montague AF</AU>
<TI>Penfluridol: a double blind trial in chronic schizophrenia</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1977</YR>
<VL>85</VL>
<NO>580</NO>
<PG>53-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jus-1974" NAME="Jus 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jus A, Pineau R, Jus K, Villeneuve A, Gautier J, Pires P, Drolet A, Cote M, Villeneuve R</AU>
<TI>Penfluridol: a long acting oral neuroleptic as therapeutic agent in chronic schizophrenia</TI>
<SO>Current Therapeutic Research</SO>
<YR>1974</YR>
<VL>16</VL>
<NO>10</NO>
<PG>1041-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khorana-1988" NAME="Khorana 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khorana AB, Patel Y</AU>
<TI>Comparative short-term evaluation of penfluridol and trifluoperazine in chronic schizophrenia</TI>
<SO>Indian Journal of Physiology and Pharmacology</SO>
<YR>1988</YR>
<VL>32</VL>
<NO>4</NO>
<PG>293-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurland-1975" NAME="Kurland 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurland AA, Ota KY, Slotnick VB</AU>
<TI>Penfluridol: a long-acting oral neuroleptic. A controlled study</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1975</YR>
<VL>15</VL>
<NO>8-9</NO>
<PG>611-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurland AA, Ota KY</AU>
<TI>Penfluridol: once-a-week oral maintenance neuroleptic in the management of chronic schizophrenics</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1975</YR>
<VL>11</VL>
<NO>1</NO>
<PG>12-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapierre-1978" NAME="Lapierre 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Author answered by e-mail that will send more data&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lapierre YD</AU>
<TI>A controlled study of penfluridol in the treatment of chronic schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1978</YR>
<VL>135</VL>
<NO>8</NO>
<PG>956-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munitz-1986" NAME="Munitz 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Author contacted&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munitz H, Shalev A</AU>
<TI>Loading - A beneficial therapeutic effect using an oral long-acting drug, Penfluridol (SEMAP) - a pilot study</TI>
<SO>Israel Journal of Psychiatry and Related Sciences</SO>
<YR>1986</YR>
<VL>23</VL>
<NO>3</NO>
<PG>215-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ota-1974" NAME="Ota 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ota KY, Kurland AA, Slotnick VB</AU>
<TI>Safety evaluation of penfluridol, a new long-acting oral antipsychotic agent</TI>
<SO>The Journal of Clinical Pharmacology</SO>
<YR>1974</YR>
<VL>14</VL>
<NO>4</NO>
<PG>202-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quitkin-1977" NAME="Quitkin 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quitkin F, Rifkin A Klein DF</AU>
<TI>A one-year double-blind comparison of long-acting oral (penfluridol) versus long-acting injectable (fluphenazine decanoate) antipsychotic drugs in multiple-episode schizophrenics</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1977</YR>
<VL>13</VL>
<NO>3</NO>
<PG>27-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quitkin F, Rifkin A, Kane J, Ramos-Lorenzi JR, Klein DF</AU>
<TI>Long-acting oral vs injectable antipsychotic drugs in schizophrenics: a one-year double-blind comparison in multiple episode schizophrenics</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1978</YR>
<VL>35</VL>
<NO>7</NO>
<PG>889-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roelofs-1974" NAME="Roelofs 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Allocation unclear. Sent letter to the author&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roelofs GA</AU>
<TI>Penfluridol (R 16341) as a maintenance therapy in chronic psychotic</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1974</YR>
<VL>50</VL>
<NO>2</NO>
<PG>219-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vandecasteele-1974" NAME="Vandecasteele 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Allocation unclear. Sent letter to the author&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vandecasteele AJ, Vereecken JL</AU>
<TI>A double-blind clinical evaluation of penfluridol (R 16 341) as a maintenance therapy in schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1974</YR>
<VL>50</VL>
<NO>3</NO>
<PG>346-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Praag-1971" NAME="Van Praag 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Praag HM, Schut T, Dols L, Van Schilfgaarden R</AU>
<TI>Controlled trial of penfluridol in acute psychosis</TI>
<SO>British Medical Journal</SO>
<YR>1971</YR>
<VL>4</VL>
<NO>789</NO>
<PG>710-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1982" NAME="Wang 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Author unknow at the adress&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wang RI, Larson C, Treul SJ</AU>
<TI>Study of penfluridol in the treatment of schizophrenia</TI>
<SO>The Journal of Clinical Pharmacology</SO>
<YR>1982</YR>
<VL>22</VL>
<NO>5-6</NO>
<PG>236-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zwanikken-1973" NAME="Zwanikken 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Author answered by e-mail that cleared up his archives&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zwanikken GJ</AU>
<TI>Penfluridol (R 16341): A long acting oral neuroleptic, as maintenance therapy for schizophrenic and mentally retarded patients - A placebo-controlled double-blind trial</TI>
<SO>Psychiatria, Neurologia, Neurochirurgia</SO>
<YR>1973</YR>
<VL>76</VL>
<NO>2</NO>
<PG>83-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-11-13 11:57:17 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abuzzahab-1977" NAME="Abuzzahab 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Sent letter to the author&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abuzzahab FS</AU>
<TI>The treatment of schizophrenia with long-acting oral neuroleptics: a six-month double-blind investigation of penfluridol versus trifluoperazine</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1977</YR>
<VL>13</VL>
<NO>3</NO>
<PG>26-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Angst-1975" NAME="Angst 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Awaiting German translation - Comparison of five depot neuroleptics for subacute and chronic schizophrenia.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angst VJ, Woggon B</AU>
<TI>Clinical study of five depot neuroleptics. Comparison of effective profiles of fluphenazinedecanoate, fluspirilene, penfluridol, perphenazine- enanthate and pipothiazinepalmitate</TI>
<TO>Klinische prufung von funf depotneuroleptika. vergleich der wirkungsprofile von fluphenazindecanoat, fluspirilen, penfluridol, perphenazinoenanthat und pipothiazinpalmitat</TO>
<SO>Arzneimittel Forschung</SO>
<YR>1975</YR>
<VL>25</VL>
<NO>2</NO>
<PG>267-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bao-1988" NAME="Bao 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bao XQ</AU>
<TI>A double-blind study of the effect of clozapine penfluridol and chlorpromazine in the treatment of schizophrenia</TI>
<SO>Chung Hua Shen Ching Ching Shen Ko Tsa Chih Chinese Journal of Neurology and Psychiatry</SO>
<YR>1988</YR>
<VL>21</VL>
<NO>5</NO>
<PG>274-6,318</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baro-1972" NAME="Baro 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baro F, Van Lommel R, Dom R, De Mesmaecker L</AU>
<TI>Pimozide treatment of chronic schizophrenics as compared with haloperidol and penfluridol maintenance treatment - a multidisciplinary approach</TI>
<SO>Acta Psychiatrica Belgica</SO>
<YR>1972</YR>
<VL>72</VL>
<NO>5</NO>
<PG>199-214</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bobon-1970" NAME="Bobon 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bobon J, Mormont C, Dufrasne M, Pinchard A</AU>
<TI>A long-acting neuroleptic. Pilot study of penfluridol (R 16341)</TI>
<TO>Neuroleptics a longue duree d'action. etude pilote du penfluridol (R 16 341)</TO>
<SO>Acta Psychiatrica Belgica</SO>
<YR>1970</YR>
<VL>70</VL>
<NO>4</NO>
<PG>523-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1977" NAME="Chouinard 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Annable L, Cooper S</AU>
<TI>Antiparkinsonian drug administration and plasma levels of penfluridol, a new long-acting neuroleptic</TI>
<SO>Communications in Psychopharmacology</SO>
<YR>1977</YR>
<VL>1</VL>
<NO>4</NO>
<PG>325-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cooper-1975" NAME="Cooper 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cooper F, Dugal R, Albert JM, Bertrand M</AU>
<TI>Penfluridol steady-state kinetics psychiatric patients</TI>
<SO>Clinical Pharmacology and Terapeutics</SO>
<YR>1975</YR>
<VL>18</VL>
<NO>3</NO>
<PG>325-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eklund-1976" NAME="Eklund 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Sent letter to the author&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eklund KL</AU>
<TI>A double blind comparison study between penfluridol and perphenazine in acute schizophrenic patients</TI>
<SO>Nordisk Psykiatrisk Tidsskrift</SO>
<YR>1976</YR>
<VL>30</VL>
<NO>5</NO>
<PG>384-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Floru-1973" NAME="Floru 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Floru L, Zurbon R</AU>
<TI>n/a</TI>
<TO>Stationäre erfahrung mit einem oralen langzeit-neuroleptikum: penfluridol</TO>
<SO>Therapeutische Erfahrungsberichte</SO>
<YR>1973</YR>
<VL>24</VL>
<PG>600-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Floru-1975" MODIFIED="2008-11-13 11:57:17 +0000" MODIFIED_BY="[Empty name]" NAME="Floru 1975" YEAR="1975">
<REFERENCE MODIFIED="2008-11-13 11:57:17 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CSG answer that it's not randomised&lt;/p&gt;" NOTES_MODIFIED="2008-11-13 11:57:17 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Floru L, Heinrich K, Wittek F</AU>
<TI>The problems of post-psychotic schizophrenic depression and their pharmacological induction:Long-term studies with fluspirilene and penfluridol and single-blind trial with fluphenazine-decanoate and flupenthixol-decanoate</TI>
<SO>International Pharmacopsychiatria</SO>
<YR>1975</YR>
<VL>10</VL>
<NO>4</NO>
<PG>230-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallant-1975" NAME="Gallant 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;CSG answer that it's not randomised&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallant DM</AU>
<TI>Potential value of penfluridol and pipothiazine palmitate</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1975</YR>
<VL>11</VL>
<NO>1</NO>
<PG>11-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glatzel-1973" NAME="Glatzel 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glatzel J</AU>
<TI>Not available</TI>
<TO>Bericht über die klinishe prüfung des langzeit-neurolepticums penfluridol</TO>
<SO>Therapeutische Erfahrunghsberichte</SO>
<YR>1973</YR>
<VL>not found</VL>
<PG>2044-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hasse-1971" NAME="Hasse 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hasse HJ, Fischer D, Floru L, Frank Th, Joseph K, Knaack M, Mohr W, Richter-Peill H, Steuer A, Wahl G, Walterbusch G, Zurborn R</AU>
<TI>Not available</TI>
<TO>Zum gegenwärtigen stand der behandlung mit langzeitneuroleptica unter besonderer berücksichtigung von fluspirilene und penfluridol</TO>
<SO>Der Nervenarzt</SO>
<YR>1971</YR>
<VL>42</VL>
<NO>12</NO>
<PG>632-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kingstone-1977" NAME="Kingstone 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kingstone E, Grof P, Furlong W, Jacques W, Virc L, Daigle L</AU>
<TI>Penfluridol, a peroral long-acting neuroleptic, for the maintenance treatment of schizophrenic patients who relapse</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1977</YR>
<VL>17</VL>
<NO>4</NO>
<PG>252-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-1987" NAME="Li 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;e-mail from Kristian, the author of Clozapine review excluding this study&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Y</AU>
<TI>Application of NOSIE in the study of neuroleptic treatment</TI>
<SO>Chung Hua Shen Ching Ching Shen Ko Tsa Chih Chinese Journal of Neurology and Psychiatry</SO>
<YR>1987</YR>
<VL>20</VL>
<PG>325-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linden-1973" NAME="Linden 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Awaiting Germany translation&lt;/p&gt;" PRIMARY="NO" TYPE="BOOK">
<AU>Linden KJ, Knaack M, Edel W</AU>
<TI>Combination of rating scales and handwriting tests for objective evaluation and quantifying neuroleptic effects. A double blind study with fluspirilene and penfluridol</TI>
<TO>Die kombination von rating scales und handschrifttest zur objektivierung und quantifizierung neuroleptischer effekte. Eine doppelblindstudie mit fluspirilene und penfluridol</TO>
<SO>Psychopharmacology, sexual disorders and drug abuse</SO>
<YR>1973</YR>
<PG>273-8</PG>
<PB>Medical press</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morales-1981" NAME="Morales 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morales E, Levy V, Schilkrut R</AU>
<TI>Antipsychotics and the re-socializing effect of penfluridol</TI>
<TO>Evaluación de un neuroléptico de acción prolongada: penfluridol - evolución clínica y psycossocial en un año de seguimiento</TO>
<SO>Acta Psiquiátrica y psicologica del America Latina</SO>
<YR>1981</YR>
<VL>27</VL>
<PG>186-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nistico-1974" NAME="Nistico 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Allocation unclear. Sent letter to the author&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nistico G, Ragozzino D, Marano V</AU>
<TI>A comparative study of penfluridol and flupentixol in the treatment of chronic schizophrenia</TI>
<SO>The Journal of Clinical Pharmacology</SO>
<YR>1974</YR>
<VL>14</VL>
<NO>8-9</NO>
<PG>476-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richards-1976" NAME="Richards 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richards MS, Zelaschi NM, Canero E</AU>
<TI>not available</TI>
<TO>Actividad de un nuevo neuroléptic, penfluridol (R 163410 en tratamientos de larga duración</TO>
<SO>Acta psiquiátrica y Psicológica del América Latina</SO>
<YR>1976</YR>
<VL>22</VL>
<PG>205-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-1988" NAME="Sharma 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma SD</AU>
<TI>Penfluridol in the treatment of schizophrenics</TI>
<SO>Indian Journal of Psychiatry</SO>
<YR>1988</YR>
<VL>30</VL>
<NO>4</NO>
<PG>405-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shopsin-1977" NAME="Shopsin 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shopsin B, Klein H, Gerbino L, Selzer G</AU>
<TI>Penfluridol: an open III study in acute newly admitted hospitalized schizophrenic patients</TI>
<SO>Psychopharmacology</SO>
<YR>1977</YR>
<VL>55</VL>
<PG>157-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanghe-1972" NAME="Tanghe 1972" YEAR="1972">
<REFERENCE NOTES="&lt;p&gt;Allocation unclear. e-mail p/ autor SR of Fluspirilene - CSG answer that it's not randomised&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanghe A, Vereecken JLTM</AU>
<TI>Fluspirilene, an injectable and penfluridol, an oral long-acting, neuroleptic. A comparative double-blind trial in residual schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1972</YR>
<VL>48</VL>
<NO>4</NO>
<PG>315-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaidyalingam-1990" NAME="Vaidyalingam 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaidyalingam N</AU>
<TI>Evaluation of penfluridol in hospitalised chronic schizophrenics</TI>
<SO>Journal of Postgraduated Medicine</SO>
<YR>1990</YR>
<VL>36</VL>
<NO>2</NO>
<PG>100-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Lommel-1974" NAME="Van Lommel 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Clinical trial (Haloperidol x Penfluridol). Allocation procedure unclear. Clinical outcomes not presented.&lt;br&gt;Sent letter to the author&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Lommel R, Baro F, Dom R</AU>
<TI>The influence of haloperidol and penfluridol on the learning capacity of the schizophrenic</TI>
<SO>Arzneimittel Forschung</SO>
<YR>1974</YR>
<VL>24</VL>
<NO>7</NO>
<PG>1072-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woggon-1978" NAME="Woggon 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woggon B</AU>
<TI>Penfluridol - results of a year-long clinical trial</TI>
<TO>Penfluridol - ergebnisse einer einjjahrigen klinischen prufung</TO>
<SO>International Pharmacopsychiatry</SO>
<YR>1978</YR>
<VL>13</VL>
<NO>1</NO>
<PG>1-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-11-07 10:45:36 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Baro-1972a" MODIFIED="2012-09-10 09:14:04 +0100" MODIFIED_BY="[Empty name]" NAME="Baro 1972a" YEAR="1972">
<REFERENCE MODIFIED="2012-09-10 09:14:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baro F, Van Lommel R, Dom R, De Mesmaecker L</AU>
<TI>Pimozide treatment of chronic schizophrenics as compared with haloperidol and penfluridol maintenance treatment. A multidisciplinary approach</TI>
<SO>Acta Psychiatrica Belgica</SO>
<YR>1972</YR>
<VL>72</VL>
<NO>2</NO>
<PG>199-214</PG>
<IDENTIFIERS MODIFIED="2012-09-10 09:13:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="5056015"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duval-2006" MODIFIED="2012-09-10 09:13:03 +0100" MODIFIED_BY="[Empty name]" NAME="Duval 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-09-10 09:13:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duval F, Chokmani N, MokraniC, He J, Macher JP</AU>
<TI>Prolactin response to oral and long-acting forms of risperidone in schizophrenic patients</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S440</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Intoh-1990" MODIFIED="2012-09-10 09:17:24 +0100" MODIFIED_BY="[Empty name]" NAME="Intoh 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-09-10 09:17:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Intoh P, Charkrabhandu S</AU>
<TI>Penfluridol: a double blind trial in Thai chronic schizophrenics</TI>
<SO>Journal of the Psychiatric Association of Thailand</SO>
<YR>1990</YR>
<VL>35</VL>
<PG>128-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Itoh-1976" NAME="Itoh 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Awaiting assessment&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Itoh H, Miura S, Yagi G, Ogita K, Ohtska, Kogay, Okamoto M, Ohtsuka T, Kasahara T, Hara Y, Sakurai S, Suzuki T, Maeshiro S, Tashiro I, Kunitoshi K</AU>
<TI>Comparison of clinical effects of penfluridol, a long-acting oral neuroleptic, and perphenazine in schizophrenia using double-blind technique</TI>
<SO>Rinsho Hyoka (Clinical Evaluation)</SO>
<YR>1976</YR>
<VL>4</VL>
<NO>1</NO>
<PG>101-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-1995" MODIFIED="2012-09-10 09:18:46 +0100" MODIFIED_BY="[Empty name]" NAME="Jiang 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-09-10 09:18:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiang L</AU>
<TI>A control study of haloperidol decanoate ampoul and penfluridol in treating chronic schizophrenia</TI>
<SO>Medical Journal of Chinese Civil Administration</SO>
<YR>1995</YR>
<VL>3</VL>
<PG>140-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jus-1976" MODIFIED="2012-09-10 09:13:03 +0100" MODIFIED_BY="[Empty name]" NAME="Jus 1976" YEAR="1976">
<REFERENCE MODIFIED="2012-09-10 09:13:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jus A, Pineau R, Villeneuve A, Gautier J, Jus K</AU>
<TI>A long-term study of penfluridol in chronic schizophrenia</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1976</YR>
<VL>16</VL>
<PG>298-303</PG>
<IDENTIFIERS MODIFIED="2012-09-10 09:13:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="14-01326"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kondo-1975" NAME="Kondo 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kondo H, Imai H, Takahashi S</AU>
<TI>Comparison of the clinical efficacy of penfluridol and carpipramine for schizophrenia by the double-blind method</TI>
<SO>Seishin Igaku (Clinical Psychiatry)</SO>
<YR>1975</YR>
<VL>4</VL>
<NO>11</NO>
<PG>1373-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shu-1983" MODIFIED="2012-09-10 09:19:10 +0100" MODIFIED_BY="[Empty name]" NAME="Shu 1983" YEAR="1983">
<REFERENCE MODIFIED="2012-09-10 09:19:10 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Awaiting chinese translation&lt;/p&gt;" NOTES_MODIFIED="2012-09-10 09:19:10 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shu L</AU>
<TI>Double-blind study of domestic penfluridol and fluphenazine decanoate</TI>
<SO>Chinese Journal of Neurology and Psychiatry</SO>
<YR>1983</YR>
<VL>16</VL>
<NO>3</NO>
<PG>141-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strous-2007" MODIFIED="2012-09-10 09:19:22 +0100" MODIFIED_BY="[Empty name]" NAME="Strous 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-09-10 09:19:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strous RD, Greenbaum L, Kanyas K, Merbl Y, Horowitz A, Karni O, et al</AU>
<TI>Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2007</YR>
<VL>10</VL>
<NO>3</NO>
<PG>321-33</PG>
<IDENTIFIERS MODIFIED="2012-09-10 09:13:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="16734940"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xun-2006" MODIFIED="2012-09-10 09:19:32 +0100" MODIFIED_BY="[Empty name]" NAME="Xun 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-09-10 09:19:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xun ZY</AU>
<TI>A study on schizophrenia hiddenly treated with risperidone oral solution and penfluridol</TI>
<TO>&#21033;&#22521;&#37230;&#21475;&#26381;&#28082;&#19982;&#20116;&#27679;&#21033;&#22810;&#26263;&#26381;&#33647;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Shandong Jingshen Yixue</SO>
<YR>2006</YR>
<VL>19</VL>
<NO>1</NO>
<PG>37-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x0e1b__x0e23__x0e35__x0e0a__x0e32_-2533" MODIFIED="2012-09-10 09:13:03 +0100" MODIFIED_BY="[Empty name]" NAME="&#3611;&#3619;&#3637;&#3594;&#3634; 2533" YEAR="2533">
<REFERENCE MODIFIED="2012-09-10 09:13:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#3611;&#3619;&#3637;&#3594;&#3634; &#3629;&#3636;&#3609;&#3650;&#3607;, &#3626;&#3617;&#3594;&#3634;&#3618; &#3592;&#3633;&#3585;&#3619;&#3614;&#3633;&#3609;&#3608;&#3640;&#3660; &#3617; &#3621;</AU>
<TI>Study results of drug penfluridol in patients with chronic schizophrenia</TI>
<TO>&#3585;&#3634;&#3619;&#3624;&#3638;&#3585;&#3625;&#3634;&#3612;&#3621;&#3586;&#3629;&#3591;&#3618;&#3634; penfluridol &#3651;&#3609;&#3588;&#3609;&#3652;&#3586;&#3657;&#3592;&#3636;&#3605;&#3648;&#3616;&#3607;&#3648;&#3619;&#3639;&#3657;&#3629;&#3619;&#3633;&#3591;</TO>
<SO>Magazine Association of Thailand</SO>
<YR>2533</YR>
<VL>35</VL>
<NO>3</NO>
<PG>128-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5b59__x8f7b__x9a91_-2007" MODIFIED="2012-11-07 10:45:36 +0000" MODIFIED_BY="[Empty name]" NAME="&#23385;&#36731;&#39569; 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-09-10 09:21:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#23385;&#36731;&#39569;, &#20446;&#38196;, &#40644;&#24314;&#40857;, &#21608;&#24314;&#32418;</AU>
<TI>The cost of the two treatment regimens in the treatment of schizophrenia - effect analysis</TI>
<TO>&#20004;&#31181;&#27835;&#30103;&#26041;&#26696;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#25104;&#26412;-&#25928;&#26524;&#20998;&#26512;</TO>
<SO>Herald of Medicine [&#21307;&#33647;&#23548;&#25253;] [&#37291;&#34277;&#23566;&#22577;]</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>7</NO>
<PG>815-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-09-10 09:26:43 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-09-10 09:26:43 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Almeida_x002d_Filho-1997" NAME="Almeida-Filho 1997" TYPE="JOURNAL_ARTICLE">
<AU>Almeida-Filho N, Mari JJ, Coutinho ESF, França J, Fernandes J, Andreoli SB, Busnello ED</AU>
<TI>Brazilian multicentric study of psychiatry morbidity: methodological features and prevalence estimates</TI>
<TO>Estudo multicêntrico de morbidade psiquiátrica em áreas urbanas brasileiras (Brasilia, São Paulo, Porto Alegre)</TO>
<SO>British Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>171</VL>
<PG>524-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF</AU>
<TI>Improving the quality of reporting of randomized controlled trials: the CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>8</NO>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter Jr WT, Buchanam RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazier LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>6</NO>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83 876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<TO>Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology</TO>
<SO>National Institute of Mental Health Publication No.76-33</SO>
<YR>1976</YR>
<PB>US Government Printing Office</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2012-09-10 09:26:43 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2005" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</SO>
<YR>2005</YR>
<PB>John Wiley &amp; Sons, Ltd.</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Janssen-1970" NAME="Janssen 1970" TYPE="JOURNAL_ARTICLE">
<AU>Janssen PAJ, Niemergeers CJE, Schellekens KHL</AU>
<TI>The pharmacology of penfluridol (R16341): a new potential and orally long-acting neuroleptic drug</TI>
<SO>European Journal of Pharmacology</SO>
<YR>1970</YR>
<VL>11</VL>
<PG>139-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Janssen-1972" NAME="Janssen 1972" TYPE="JOURNAL_ARTICLE">
<AU>Janssen PAJ</AU>
<TI>Long-acting neuroleptics and other psychoactive drugs on the future</TI>
<SO>Clinical Medicine</SO>
<YR>1972</YR>
<VL>79</VL>
<PG>12-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Jounal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman DG, for the CONSORT Group</AU>
<TI>Revised recommendations for improving the quality of reports of parallel group randomized trials 2001</TI>
<SO>The Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<PG>1191-1194</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1961" NAME="Overall 1961" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DE</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychology Reports</SO>
<YR>1961</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Haues RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shapiro-1983" NAME="Shapiro 1983" TYPE="JOURNAL_ARTICLE">
<AU>Shapiro AK, Shaouro E, Eidenkraft GJ</AU>
<TI>Treatment of Tourette disorder with penfluridol</TI>
<SO>Compr Psychiatry</SO>
<YR>1983</YR>
<VL>24</VL>
<NO>4</NO>
<PG>327-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Torrey-1987" NAME="Torrey 1987" TYPE="JOURNAL_ARTICLE">
<AU>Torrey EF</AU>
<TI>Prevalence studies in schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>150</VL>
<PG>598-608</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>1-75</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-09-10 09:16:41 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Baro-1970">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 10 months.<BR/>Design: 2 parallel groups, two phases - 1st uncontrolled study for 8 months; 2nd RCT for more than 8 weeks.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=26.<BR/>Age: 24-70 years.<BR/>Sex: male.<BR/>Setting: inpatient.<BR/>History: unclear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 10-40 mg/week. N=13.</P>
<P>2. Placebo. N=13.</P>
<P>Dexbenzetimide for EPSE as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.</P>
<P>Unable to use -<BR/>Global state: FCRS (no data).<BR/>Mental state: PEQ (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Channabasavanna-1987">
<CHAR_METHODS>
<P>Allocation: randomised.<BR/>Blindness: double, identical capsules.<BR/>Duration: 12 weeks.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-III).<BR/>N=30.<BR/>Age: mean ~ 36 years.<BR/>Sex: 16M, 12F*.<BR/>History: mean length of illness ~ 11 years, well maintained on antipsychotics, physically healthy.<BR/>Setting: unclear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 20 mg on day 1, 40 mg on day 7, 60 mg on day 14 and weekly thereafter. N=15.</P>
<P>2. Placebo. N=15.</P>
<P>Trihexyphenidyl as required for EPSE.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: needing additional antipsychotic drugs.<BR/>Leaving the study early.<BR/>Adverse events: medication for parkinsonian symptoms.</P>
<P>Unable to use -<BR/>Global state: time to use additional antipsychotic drugs (idiosyncratic reporting of non-pre-specified outcome).<BR/>Mental state: SANS, SAPS (no data).<BR/>Adverse events: Simpson and Angus Scale (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* sex of 2 participants not given.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Charalampous-1977">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 26 weeks.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=55.<BR/>Age: 21-55 years, mean ~ 35 years.<BR/>Sex: male.<BR/>History: chronic schizophrenia, mean length of illness 7.9 years.<BR/>Setting: inpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 20-140 mg/week. N=28.</P>
<P>2. Fluphenazine: dose oral 21-147 mg/day N=27.</P>
<P>Benztropine mesylate for EPSE, and chloral hydrate for insomnia.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: CGI improved/not improved.<BR/>Leaving the study early.<BR/>Adverse events: medication for parkinsonian symptoms.</P>
<P>Unable to use -<BR/>Mental state: BPRS (no data).<BR/>Behaviour: NOSIE (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chouinard-1976">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 3 weeks.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-II).<BR/>N=33.<BR/>Age: unclear.<BR/>Sex: male and female, numbers unclear.<BR/>History: unclear.<BR/>Setting: inpatients (brief therapy unit).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 40 mg on day 1, 80 mg on day 7, 120 mg on day 14. N=14.</P>
<P>2. Chlorpromazine: dose 300 mg/day for week 1, 600 mg/day for week 2, 900 mg/day for week 3. N=19.</P>
<P>Procyclidine HCL for EPSE.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: needing additional antipsychotic drugs.<BR/>Leaving the study early.<BR/>Adverse events: medication for parkinsonian symptoms.</P>
<P>Unable to use -<BR/>Global state: CGI (no data).<BR/>Mental state: BPRS, IMPS (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Claghorn-1979">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 52 weeks.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=56.<BR/>Age: mean ~ 37 years.<BR/>Sex: 32M, 24F.<BR/>History: mean length of illness 10 years.<BR/>Setting: outpatients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose maximum 160 mg/week. N=28.</P>
<P>2. Chlorpromazine: dose maximum 5320 mg/week. N=28.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Adverse events.</P>
<P>Unable to use -<BR/>Global state: CGI (no data).<BR/>Mental state: BPRS (no data).<BR/>Social function: ESF (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-D_x0027_Elia-1977">
<CHAR_METHODS>
<P>Allocation: rated by a physician, no further details.<BR/>Blindness: open.<BR/>Duration: 4 weeks.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=28.<BR/>Age: 19-63 years.<BR/>Sex: 22M, 6F.<BR/>History: length of illness, 1-38 years, duration of hospitalisation 5 days-32 years.<BR/>Setting: inpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose no further details. N=14.</P>
<P>2. Thiothixene: dose no further details. N=14.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.</P>
<P>Unable to use -<BR/>Changes in psychopathology: (no usable data).<BR/>EEG variables: (no usable data).<BR/>Visual averaged evoked responses: (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The main aim of the study was to find out if outcome could be predicted by the EEG or VAER (visual averaged evoked response results obtained before treatment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Deutsch-1976">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: 2 parallel groups, two phases - 1st uncontrolled study for 12 weeks; 2nd RCT for 12 weeks.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: chronic schizophrenia, no further details<BR/>N=37.<BR/>Age: unclear.<BR/>Sex: unclear.<BR/>History: unclear.<BR/>Setting: inpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 20-140 mg/week. N=18.</P>
<P>2. Placebo: N=19.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: CGI improved/not improved.<BR/>Adverse events: number of participants presenting at least one adverse effect.</P>
<P>Unable to use -<BR/>Mental state: BPRS (no data).<BR/>Behaviour: NOSIE (no data).<BR/>Adverse events: TESS (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Donlon-1978">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 52 weeks.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=25.<BR/>Age: mean ~ 40 years.<BR/>Sex: 12M, 13F.<BR/>History: chronic, healthy, none had been hospitalised six months previously.<BR/>Setting: outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 20-160 mg/week. N=12.</P>
<P>2. Trifluoperazine: dose 14-40 mg/day N=13.</P>
<P>Thioridazine for extra-medication.<BR/>Benztropine mesylate or trihexyphenidyl HCL for EPSE.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: CGI improved/not improved, needing additional antipsychotic drugs.<BR/>Leaving the study early.<BR/>Adverse events.</P>
<P>Unable to use -<BR/>Mental state: BPRS (no data).<BR/>Adverse events: TESS (no data).<BR/>Social functioning: ESFR (no data).<BR/>Depression: HPRSD (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Doongaji-1988">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, all patients received capsules and injections.<BR/>Duration: 12 weeks.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (RDC).<BR/>N=40.<BR/>Age: mean ~ 28 years.<BR/>Sex: 27M, 13F.<BR/>History: chronic and sub-chronic schizophrenia, mean length of illness ~2.3 years, physically healthy.<BR/>Setting: unclear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 20 mg on day 1, 40 mg on day 7, 60 mg on day 14 and thereafter. N=21.</P>
<P>2. Fluphenazine decanoate: dose 12.5 mg/IM on days 1&amp; 7, <BR/>14.25 mg/IM weekly thereafter. N=19.</P>
<P>Promethazine hydrochloride, benzhexol hydrochloride as needed for EPSE, and chloral hydrate or nitrazepam for insomnia.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Adverse events.</P>
<P>Unable to use -<BR/>Global state: CGI (no SD).<BR/>Mental state: MRS, BPRS (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gallant-1974">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=50.<BR/>Age: 24-59 years, mean ~ 41 years.<BR/>Sex: 25M, 25F.<BR/>History: severely chronically ill patients, median years of hospitalisation ~ 15 years, 12 weeks previous to the trial patients were stabilised on haloperidol (n=31) or penfluridol (n=19).<BR/>Setting: inpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose maximum 160 mg/week N=25.</P>
<P>2. Placebo N=25.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: CGI improved/not improved.<BR/>Adverse events.</P>
<P>Unable to use - <BR/>Mental state: BPRS (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gerlach-1975">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=60.<BR/>Age: 18-70 years.<BR/>Sex: males.<BR/>History: illness &lt;2 years.<BR/>Setting: in/outpatients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 20 mg/week N=30.</P>
<P>2. Flupenthixol decanoate: dose 20-100 mg/biweekly. N=30.</P>
<P>Additional: chlorprothixene, procyclidine, amitriptyline, nitrazepam, choralodol.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: CGI improved/not improved.<BR/>Leaving the study early.<BR/>Adverse events: various side effects, use of additional antipsychotic drugs.</P>
<P>Unable to use -<BR/>Mental state: BPRS (no data).<BR/>Behaviour: NOSIE (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ionescu-1983">
<CHAR_METHODS>
<P>Allocation: no information on allocation procedure.<BR/>Blindness: open.<BR/>Duration: one year.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: Kreplian sense schizophrenia.<BR/>N=60.<BR/>Age: 18-49 years, mean ~27 years.<BR/>Sex: 36M, 24F.<BR/>History: mean length of illness ~3.8 years.<BR/>Setting: in/outpatients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 20-60 mg/week, mean dose ~30 mg/week. N=30.</P>
<P>2. Fluphenazine decanoate: dose mean 7.01 mg/week. N=30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: CGI improved/not improved, needing additional antipsychotic drugs.<BR/>Mental state: BPRS.<BR/>Adverse events: several, medication for parkinsonian symptoms.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Iqbal-1978">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 52 weeks.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=38.<BR/>Age: 18-70 years, mean ~37 years.<BR/>Sex: 19M, 19F.<BR/>History: length of illness 1.5 - 28 years.<BR/>Setting: outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose mean 67 mg/week. N=17.</P>
<P>2. Fluphenazine decanoate: dose mean 25.5 mg/week. N=21.</P>
<P>Additional: chloral hydrate for insomnia, benztropine mesylate for EPSE.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: use of additional antipsychotics<BR/>Leaving the study early.<BR/>Adverse events: number of participants presenting at least one side effect, medication for parkinsonian symptoms.</P>
<P>Unable to use -<BR/>Global state: CGI (no data).<BR/>Mental state: BPRS (no data) .<BR/>Social function: ESFR (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author informed that there was allocation concealment, but did not provide details.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jacobsson-1976">
<CHAR_METHODS>
<P>Allocation: no information on allocation procedure.<BR/>Blindness: double.<BR/>Duration: 10 weeks.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia or paranoid syndromes, no further details.<BR/>N=57.<BR/>Age: 19-63 years, mean ~41 years.<BR/>Sex: 42M, 15F.<BR/>History: length of illness 1-38 years, mean ~17 years.<BR/>Setting: inpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 20-80 mg/week, mean dose 46.7 mg/week. N=29.</P>
<P>2. Thiothixene: dose 30-100 mg/day, mean dose 48.3 mg/day. N=28.</P>
<P>Additional: hypnotics for insomnia, and biperiden for EPSE.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: use of additional antipsychotic drugs.<BR/>Leaving the study early.<BR/>Adverse events: several, medication for parkinsonian symptoms.</P>
<P>Unable to use -<BR/>Nurses scale (no data).<BR/>Doctors rating (S-scale) (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-James-1977">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 24 weeks (week 1-8 dosage adjustment period).<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=16.<BR/>Age: 20-55 years.<BR/>Sex: unclear.<BR/>History: chronic illness (ill at least 1 year), physically healthy.<BR/>Setting: inpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 20-60 mg/week, mean 35 mg/week. N=8.</P>
<P>2. Fluphenazine decanoate: dose 12.5-35.5 mg/month, mean 35.5 mg/month. N=8.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving study early.<BR/>Adverse events: several, medication for parkinsonian symptoms.</P>
<P>Unable to use -<BR/>Mental state: BPRS, FCRS (no data).<BR/>Behaviour: NOSIE (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jus-1974">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 12 weeks, preceded by 20 weeks open phase with penfluridol.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=42*.<BR/>Age: unclear.<BR/>Sex: unclear.<BR/>History: chronic illness.<BR/>Setting: inpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose mean 68 mg/week. N=20.</P>
<P>2. Thioridazine: dose mean 312 mg/day, max 700 mg/day N=19.</P>
<P>Antiparkinsonians for EPSE (no more data).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: use of additional antipsychotic drug.<BR/>Adverse events.</P>
<P>Unable to use -<BR/>Global state: CGI (no data for separated intervention).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*Three participants dropped out in RCT with no information from which group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Khorana-1988">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, identical capsules and administration.<BR/>Duration: 12 weeks.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=50.<BR/>Age: mean ~ 29 years*.<BR/>Sex: 21M, no further details*.<BR/>History: chronic illness.<BR/>Setting: unclear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 20 mg/week. N=unclear.</P>
<P>2. Trifluoperazine: dose 10 mg/day. N=unclear.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse events: several, medication for parkinsonian symptoms.</P>
<P>Unable to use -<BR/>Mental state: BPRS, Hamilton, Wing, Venables, and O'Connor (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* Authors described data just for completers (Penfluridol N=15 and Trifluoperazine N=17).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kurland-1975">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=35.<BR/>Age: 21-60 years, mean ~ 43 years.<BR/>Sex: 19M, 16F.<BR/>History: chronically ill, stabilised for 12 weeks using penfluridol.<BR/>Setting: outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 20-120 mg/week. N=18.</P>
<P>2. Placebo: N=17.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: CGI improved/not improved, use of additional antipsychotic drugs.<BR/>Leaving the study early.</P>
<P>Unable to use -<BR/>Mental state: BPRS (no data).<BR/>Behaviour: NOSIE (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lapierre-1978">
<CHAR_METHODS>
<P>Allocation: randomised, sealed bottles and envelopes.<BR/>Blindness: double, no further details.<BR/>Duration: 52 weeks.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=41.<BR/>Age: 18 -52 years, mean ~ 37 years.<BR/>Sex: 24M, 17F.<BR/>History: mean duration of illness ~8.9 years, physically healthy.<BR/>Setting: inpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 20-120 mg/week, mean dose ~60.9 mg/week N=20.</P>
<P>2. Fluphenazine: dose oral 3-18 mg/day, mean dose 9.2 mg/day. N=21.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: BPRS.<BR/>Leaving the study early.<BR/>Adverse events: several, medication for parkinsonian symptoms.</P>
<P>Unable to use -<BR/>Social function: Katz social adjustment scale (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author was contacted and informed randomisation procedure.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Munitz-1986">
<CHAR_METHODS>
<P>Allocation: randomised*.<BR/>Blindness: double, no further details.<BR/>Duration: 6 weeks.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-III).<BR/>N=20.<BR/>Age: mean ~ 33 years.<BR/>Sex: 14M, 6F.<BR/>History: newly admitted, drug free for at least a month.<BR/>Setting: inpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 20 mg for weeks 1-6. N=10.</P>
<P>2. Penfluridol: dose 20 mg for weeks 2-6 (preceded by one week of placebo). N=10.</P>
<P>Benzhexol for EPSE.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse events.</P>
<P>Unable to use -<BR/>Global state: CGI (no data).<BR/>Mental state: BPRS (no data).<BR/>Behaviour: NOSIE (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* Recruitment of patients was carried out in the emergency unit by a physician who did not participate in the study. The random numbers were kept by the nursing staff. The treatment physician was blind to the assignment. The medication was administered by the nursing staff. Data obtained by the author of the study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ota-1974">
<CHAR_METHODS>
<P>Allocation: randomised, divided in 2 groups with 2 randomisation procedures performed.<BR/>Blindness: open.<BR/>Duration: 17 weeks.<BR/>Design: 4 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details. <BR/>N=18.<BR/>Age: 21-60 years, mean ~ 43 years.<BR/>Sex: unclear.<BR/>History: length of illness at least 1.5 years, good physical conditions.<BR/>Setting: inpatients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 5-200 mg/week. N=12.</P>
<P>2. Atypical antipsychotics. N=6.</P>
<P>Additional: haloperidol as extra antipsychotic; benztropine mesylate for EPSE.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.</P>
<P>Unable to use -<BR/>Global state: CGI (no data), needing additional antipsychotic drugs (no data).<BR/>Mental state: BPRS (no data).<BR/>Behaviour: NOSIE (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Quitkin-1977">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 52 weeks.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: RDC schizophrenia.<BR/>N=60.<BR/>Age: 17-48 years.<BR/>Sex: 41M, 19F.<BR/>History: unclear.<BR/>Setting: inpatients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 20-160 mg/week. N=30.</P>
<P>2. Fluphenazine decanoate: dose 0.5-4 ml/fortnightly. N=30.</P>
<P>Flurazepam HCL for insomnia, and procyclidine HCL for EPSE.<BR/>Psychotherapy, and recreation groups.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Adverse events.</P>
<P>Unable to use -<BR/>Global state: CGI (no data).<BR/>Mental state: BPRS (no data).<BR/>Social function: SAS (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Roelofs-1974">
<CHAR_METHODS>
<P>Allocation: divided into two groups by an unbiased statistician, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 6 months.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: chronic psychotic patients, no further details.<BR/>N=15.<BR/>Age: 25-64 years, mean ~ 54 years.<BR/>Sex: 6M, 9F.<BR/>History: hospitalisation 1-31 years, mean ~5 years.<BR/>Setting: inpatients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose mean 40 mg/week. N=7.</P>
<P>2. Placebo. N=8.</P>
<P>Dexitimine 1 mg/day (mean dose).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: needing additional antipsychotic drugs.</P>
<P>Unable to use -<BR/>Rating scale for psychiatric evaluation (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Van-Praag-1971">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 4 weeks.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: acute psychosis, no further details.<BR/>N=34.<BR/>Age: 19-70 years, mean ~ 41 years.<BR/>Sex: unclear.<BR/>History: admitted to a university psychiatric clinic with acute psychosis.<BR/>Setting: unclear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 30 mg/week + dexitimine 0.5 mg/day. N=20.</P>
<P>2. Placebo. N=14.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: needing additional antipsychotic drugs.<BR/>Leaving the study early.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Vandecasteele-1974">
<CHAR_METHODS>
<P>Allocation: divided into two groups by an unbiased statistician, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 6 months.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: chronic schizophrenia (DSM-II).<BR/>N=21.<BR/>Age: 25-64 years, mean ~59 years.<BR/>Sex: females.<BR/>History: hospitalisation 2-41 years, mean 27 years.<BR/>Setting: inpatients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 20-120 mg/week, mean 40 mg/week. N=11.</P>
<P>2. Placebo. N=10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: needing additional antipsychotic drugs.<BR/>Adverse events: several, medication for parkinsonian symptoms.</P>
<P>Unable to use -<BR/>General symptoms rating scale (no data, Zwanikken 1971).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wang-1982">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, capsules of identical appearance.<BR/>Duration: 12-20 weeks, preceded by 4-12 weeks on penfluridol.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=41.<BR/>Age: 20-60 years.<BR/>Sex: males.<BR/>History: unclear.<BR/>Setting: unclear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose 20-140 mg/week. N=21.</P>
<P>2. Chlorpromazine: dose 150-1050 mg/day. N=20.</P>
<P>Medication on twice-a-day schedule, benztropine mesylate and chloral hydrate as needed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: use of additional antipsychotic drugs.<BR/>Leaving the study early.<BR/>Adverse events: medication for parkinsonian symptoms.</P>
<P>Unable to use -<BR/>Global state: CGI (no SD).<BR/>Mental state: BPRS (no SD).<BR/>Behaviour: NOSIE (no SD).<BR/>Social functioning: ESF (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>It is described in the paper that there were no statistical differences in scale-derived data, and that people on penfluridol had akathisia more frequently than those on chlorpromazine, but no data presented.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zwanikken-1973">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 6 months preceded by 3 months of an open phase.<BR/>Design: 2 parallel groups.<BR/>Analysis: non ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-II), (n=17) and mental retardation (n=20).<BR/>N=37.<BR/>Age: 22-74 years, mean ~ 46 years.<BR/>Sex: females.<BR/>History: length of illness 1-53 years, mean 16.5 years.<BR/>Setting: inpatients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: dose mean 57.3 mg/week. N=20.</P>
<P>2. Placebo. N=17.</P>
<P>Haloperidol as a possible extra medication; dexitimine 0.5 mg/week for extrapyramidal symptoms.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: Zwanikken scale, use of additional antipsychotic drugs.</P>
<P>Unable to use -<BR/>Adverse events: medication for parkinsonian symptoms (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author contacted.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Diagnostic tools<BR/>DSM-II - Diagnostic Statistical Manual, version 2<BR/>DSM-III - Diagnostic Statistical Manual, version 3<BR/>RDC - Research Diagnostic Criteria</P>
<P>Rating scales:</P>
<P>Global state -<BR/>CGI - Clinical global impression<BR/>FCRS - Factor construct rating scale<BR/>Zwanikken scale</P>
<P>Mental state -<BR/>BPRS - Brief psychiatric rating scale<BR/>IMPS - Impatient multidimensional psichiatric scale<BR/>PEQ - Psychiatric Evaluation Questionnaire<BR/>SANS - Scale for assessment of negative synptoms<BR/>SAPS - Scale for assessment of positive symptoms<BR/>Scale A - Winng (1961) modified<BR/>Scale B - of authors own design</P>
<P>Behaviour -<BR/>NOSIE - Nurses observation for patient evaluation</P>
<P>Adverse events -<BR/>EPSE - Extra-pyramidal side effects MRS - Modified Rating Scale<BR/>TESS - Treatment Emergent Symptom Scale</P>
<P>Depression -<BR/>HPRSD - Hamilton Psychiatric Rating Scale for Depression</P>
<P>Social function -<BR/>SAS - Social adjustment scale<BR/>ESF - Evaluation of Social Functioning<BR/>ESFR - Evaluation of Social Functioning Factors</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Abuzzahab-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not described.<BR/>Participants: people with schizophrenia.<BR/>Interventions: penfluridol versus trifluoperazine versus stelazine.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Angst-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not described.<BR/>Participants: people with schizophrenia. <BR/>Interventions: fluphenazine versus fluspirilene versus penfluridol versus perphenazine versus pipotiazine. <BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bao-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, sequential.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baro-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bobon-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chouinard-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: penfluridol versus chlorpromazine and the use of procyclidine.<BR/>Outcomes: only data for penfluridol and procyclidine were reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cooper-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eklund-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not described.<BR/>Participants: people with schizophrenia.<BR/>Interventions: penfluridol versus perphenazine.<BR/>Outcomes: data not usable "As evident from the table, the penfluridol patients are older and have a longer period of illness behind them" (author of the study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Floru-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Floru-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gallant-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Glatzel-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hasse-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kingstone-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Li-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia. <BR/>Interventions: clozapine versus chlorpromazine versus penfluridol.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Linden-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia. <BR/>Intervention: penfluridol versus fluspirilene.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morales-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nistico-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not described.<BR/>Participants: people with schizophrenia.<BR/>Interventions: flupenthixol versus penfluridol.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Richards-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sharma-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shopsin-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tanghe-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vaidyalingam-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Lommel-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not described.<BR/>Participants: people with schizophrenia.<BR/>Interventions: penfluridol versus haloperidol versus placebo.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Woggon-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-09-10 09:16:41 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2012-09-10 09:14:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baro-1972a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-09-10 09:14:13 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-09-10 09:14:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Duval-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-09-10 09:14:22 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-09-10 09:14:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Intoh-1990">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-09-10 09:14:29 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-09-10 09:16:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Itoh-1976">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-09-10 09:16:35 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-09-10 09:16:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jiang-1995">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-09-10 09:16:36 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-09-10 09:16:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jus-1976">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-09-10 09:16:37 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-09-10 09:16:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kondo-1975">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-09-10 09:16:40 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-09-10 09:16:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shu-1983">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-09-10 09:16:40 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-09-10 09:16:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strous-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-09-10 09:16:41 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-09-10 09:15:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xun-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-09-10 09:15:00 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-09-10 09:13:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x0e1b__x0e23__x0e35__x0e0a__x0e32_-2533">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-09-10 09:13:52 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-09-10 09:13:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5b59__x8f7b__x9a91_-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-09-10 09:13:53 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Baro-1970">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Channabasavanna-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Charalampous-1977">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1976">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Claghorn-1979">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Elia-1977">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Deutsch-1976">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Donlon-1978">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Doongaji-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gallant-1974">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gerlach-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ionescu-1983">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Iqbal-1978">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jacobsson-1976">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-James-1977">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jus-1974">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Khorana-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kurland-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Lapierre-1978">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Munitz-1986">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ota-1974">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Quitkin-1977">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Roelofs-1974">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Van-Praag-1971">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vandecasteele-1974">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wang-1982">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zwanikken-1973">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-04 10:26:16 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-11-04 10:26:16 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>PENFLURIDOL versus PLACEBO</NAME>
<DICH_OUTCOME CHI2="2.8386052737911203" CI_END="0.8475683120505395" CI_START="0.5619942991182846" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6901656029430259" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="64" I2="0.0" I2_Q="46.88570122695354" ID="CMP-001.01" LOG_CI_END="-0.07182528858093123" LOG_CI_START="-0.25026808990074056" LOG_EFFECT_SIZE="-0.16104668924083593" METHOD="MH" NO="1" P_CHI2="0.41718427959495075" P_Q="0.17002415410714944" P_Z="4.035056983502393E-4" Q="1.8827321890719624" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="78" WEIGHT="100.0" Z="3.5377802680394494">
<NAME>Global state: 1. No marked improvement</NAME>
<GROUP_LABEL_1>Penfluridol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Penfluridol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9940911074176153" CI_END="0.8021373123851842" CI_START="0.4868603080398033" DF="2" EFFECT_SIZE="0.6249230504614713" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="50" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.09575128145807779" LOG_CI_START="-0.31259563046939864" LOG_EFFECT_SIZE="-0.2041734559637382" NO="1" P_CHI2="0.608325331179665" P_Z="2.2348454132934927E-4" STUDIES="3" TAU2="0.0" TOTAL_1="61" TOTAL_2="61" WEIGHT="67.71764513724932" Z="3.690874326331739">
<NAME>medium-term (CGI)</NAME>
<DICH_DATA CI_END="1.6500377148950283" CI_START="0.43216370954190675" EFFECT_SIZE="0.8444444444444444" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.21749387099184772" LOG_CI_START="-0.3643517053089147" LOG_EFFECT_SIZE="-0.07342891715853353" ORDER="7279" O_E="0.0" SE="0.34177897170112154" STUDY_ID="STD-Deutsch-1976" TOTAL_1="18" TOTAL_2="19" VAR="0.11681286549707603" WEIGHT="9.405515238669338"/>
<DICH_DATA CI_END="0.8378416231796357" CI_START="0.44098224447923534" EFFECT_SIZE="0.6078431372549019" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="25" LOG_CI_END="-0.07683806809963757" LOG_CI_START="-0.3555788964276899" LOG_EFFECT_SIZE="-0.2162084822636637" ORDER="7280" O_E="0.0" SE="0.1637337423492511" STUDY_ID="STD-Gallant-1974" TOTAL_1="25" TOTAL_2="25" VAR="0.02680873838369094" WEIGHT="40.98235324545387"/>
<DICH_DATA CI_END="0.928223435789838" CI_START="0.3459416113943226" EFFECT_SIZE="0.5666666666666667" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="-0.032347470709364314" LOG_CI_START="-0.4609971959734127" LOG_EFFECT_SIZE="-0.24667233334138852" ORDER="7281" O_E="0.0" SE="0.25179097047046284" STUDY_ID="STD-Kurland-1975" TOTAL_1="18" TOTAL_2="17" VAR="0.0633986928104575" WEIGHT="17.329776653126103"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2202541704777128" CI_START="0.5920897608710087" DF="0" EFFECT_SIZE="0.85" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.08645030062469689" LOG_CI_START="-0.22761244919611137" LOG_EFFECT_SIZE="-0.07058107428570728" NO="2" P_CHI2="1.0" P_Z="0.37834636146084377" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="17" WEIGHT="32.28235486275069" Z="0.8809472862927019">
<NAME>medium-term (Zwanikken scale)</NAME>
<DICH_DATA CI_END="1.2202541704777128" CI_START="0.5920897608710087" EFFECT_SIZE="0.85" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.08645030062469689" LOG_CI_START="-0.22761244919611137" LOG_EFFECT_SIZE="-0.07058107428570728" ORDER="7282" O_E="0.0" SE="0.18448201388042723" STUDY_ID="STD-Zwanikken-1973" TOTAL_1="20" TOTAL_2="17" VAR="0.03403361344537814" WEIGHT="32.28235486275069"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.768305690585053" CI_END="0.674250192189563" CI_START="0.28076642860654544" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.435094034029818" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.1711789210829247" LOG_CI_START="-0.5516548222635781" LOG_EFFECT_SIZE="-0.3614168716732515" METHOD="MH" NO="2" P_CHI2="0.4448059091388331" P_Q="0.9249373173831841" P_Z="1.964264866641913E-4" Q="0.008876715920088079" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="91" TOTAL_2="81" WEIGHT="200.0" Z="3.7235685607765716">
<NAME>Global state: 2. Needing additional antipsychotic</NAME>
<GROUP_LABEL_1>Penfluridol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Penfluridol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.859209376512356" CI_START="0.23094458404489043" DF="0" EFFECT_SIZE="0.44545454545454544" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-0.06590099218297873" LOG_CI_START="-0.6364922180764441" LOG_EFFECT_SIZE="-0.3511966051297114" NO="1" P_CHI2="1.0" P_Z="0.015834851383694417" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="14" WEIGHT="100.0" Z="2.412699902523518">
<NAME>short-term</NAME>
<DICH_DATA CI_END="0.8592093765123561" CI_START="0.23094458404489038" EFFECT_SIZE="0.44545454545454544" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="-0.06590099218297868" LOG_CI_START="-0.6364922180764442" LOG_EFFECT_SIZE="-0.3511966051297114" ORDER="7283" O_E="0.0" SE="0.33516811056194223" STUDY_ID="STD-Van-Praag-1971" TOTAL_1="20" TOTAL_2="14" VAR="0.11233766233766232" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.807102734065415" CI_END="0.7685559295502364" CI_START="0.2372060138316694" DF="4" EFFECT_SIZE="0.42697317065045776" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="34" I2="16.78979582329085" ID="CMP-001.02.02" LOG_CI_END="-0.11432452242421481" LOG_CI_START="-0.6248743045961351" LOG_EFFECT_SIZE="-0.369599413510175" NO="2" P_CHI2="0.30766889182448554" P_Z="0.0045435418921338545" STUDIES="5" TAU2="0.07920081474806935" TOTAL_1="71" TOTAL_2="67" WEIGHT="100.0" Z="2.8377312633663525">
<NAME>medium-term</NAME>
<DICH_DATA CI_END="0.6206576369323504" CI_START="0.044755395124229276" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.20714789642930082" LOG_CI_START="-1.3491546043379865" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="7284" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-Chouinard-1976" TOTAL_1="15" TOTAL_2="15" VAR="0.45000000000000007" WEIGHT="16.99538042760126"/>
<DICH_DATA CI_END="3.682649011147799" CI_START="0.0097484927017579" EFFECT_SIZE="0.18947368421052632" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5661603287420783" LOG_CI_START="-2.0110625291131616" LOG_EFFECT_SIZE="-0.7224511001855417" ORDER="7285" O_E="0.0" SE="1.513873464163064" STUDY_ID="STD-Kurland-1975" TOTAL_1="18" TOTAL_2="17" VAR="2.291812865497076" WEIGHT="3.7933012551450442"/>
<DICH_DATA CI_END="6.114000914056584" CI_START="0.21362810822888662" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7863254993180552" LOG_CI_START="-0.6703416053626817" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="7286" O_E="0.0" SE="0.8556534679079243" STUDY_ID="STD-Roelofs-1974" TOTAL_1="7" TOTAL_2="8" VAR="0.7321428571428572" WEIGHT="11.08527678323852"/>
<DICH_DATA CI_END="0.9393362867900428" CI_START="0.1237246020396098" EFFECT_SIZE="0.3409090909090909" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="-0.02717890043752251" LOG_CI_START="-0.9075439344234898" LOG_EFFECT_SIZE="-0.46736141743050624" ORDER="7287" O_E="0.0" SE="0.5171307788405584" STUDY_ID="STD-Vandecasteele-1974" TOTAL_1="11" TOTAL_2="10" VAR="0.26742424242424245" WEIGHT="25.947256215724074"/>
<DICH_DATA CI_END="1.219402187513014" CI_START="0.29032668927881644" EFFECT_SIZE="0.595" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.0861469697772404" LOG_CI_START="-0.5371130383201413" LOG_EFFECT_SIZE="-0.22548303427145044" ORDER="7288" O_E="0.0" SE="0.3661060139431994" STUDY_ID="STD-Zwanikken-1973" TOTAL_1="20" TOTAL_2="17" VAR="0.13403361344537812" WEIGHT="42.178785318291105"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.609116592485742" CI_END="1.7387793353910885" CI_START="0.105281990092559" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4278576267425776" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="27" I2="65.15321905828901" I2_Q="72.33807207944253" ID="CMP-001.03" LOG_CI_END="0.2402444701552442" LOG_CI_START="-0.9776459144021542" LOG_EFFECT_SIZE="-0.36870072212345506" METHOD="MH" NO="3" P_CHI2="0.03496576026771492" P_Q="0.05725825117331995" P_Z="0.23534283620518692" Q="3.615077021644725" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="2.645621978555712" TOTALS="SUB" TOTAL_1="66" TOTAL_2="59" WEIGHT="200.0" Z="1.1867080085347774">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Penfluridol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Penfluridol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.16676814484403" CI_START="0.2427509375822368" DF="0" EFFECT_SIZE="2.1" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.2592776734995144" LOG_CI_START="-0.6148390840316756" LOG_EFFECT_SIZE="0.3222192947339193" NO="1" P_CHI2="1.0" P_Z="0.5003378699294666" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="14" WEIGHT="100.0" Z="0.6739582368756106">
<NAME>short-term</NAME>
<DICH_DATA CI_END="18.16676814484403" CI_START="0.2427509375822368" EFFECT_SIZE="2.1" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2592776734995144" LOG_CI_START="-0.6148390840316756" LOG_EFFECT_SIZE="0.3222192947339193" ORDER="7289" O_E="0.0" SE="1.1008654604013888" STUDY_ID="STD-Van-Praag-1971" TOTAL_1="20" TOTAL_2="14" VAR="1.2119047619047618" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.5025713163559957" CI_END="0.8460709640921527" CI_START="0.021137586673554955" DF="2" EFFECT_SIZE="0.13373069331860984" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="26" I2="42.899092713385215" ID="CMP-001.03.02" LOG_CI_END="-0.07259320904003548" LOG_CI_START="-1.674944598589023" LOG_EFFECT_SIZE="-0.8737689038145292" NO="2" P_CHI2="0.17355102104582532" P_Z="0.03255303245865286" STUDIES="3" TAU2="1.1481513268035106" TOTAL_1="46" TOTAL_2="45" WEIGHT="99.99999999999999" Z="2.1375530903612243">
<NAME>medium-term</NAME>
<DICH_DATA CI_END="0.564333673655905" CI_START="0.002430728798436462" EFFECT_SIZE="0.037037037037037035" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="13" LOG_CI_END="-0.24846403470847606" LOG_CI_START="-2.614263493609499" LOG_EFFECT_SIZE="-1.4313637641589874" ORDER="7290" O_E="0.0" SE="1.3896823130546532" STUDY_ID="STD-Baro-1970" TOTAL_1="13" TOTAL_2="13" VAR="1.931216931216931" WEIGHT="28.769286943544877"/>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" ORDER="7291" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Channabasavanna-1987" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="29.38526611281829"/>
<DICH_DATA CI_END="0.5418504538687914" CI_START="0.01143170210978604" EFFECT_SIZE="0.0787037037037037" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.2661205585191193" LOG_CI_START="-1.9418891010261945" LOG_EFFECT_SIZE="-1.104004829772657" ORDER="7292" O_E="0.0" SE="0.9843547370567244" STUDY_ID="STD-Kurland-1975" TOTAL_1="18" TOTAL_2="17" VAR="0.968954248366013" WEIGHT="41.84544694363682"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4683433161739905" CI_END="19.73021759275065" CI_START="0.2048185559653596" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0102523911761727" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" I2="71.1677908199952" I2_Q="71.16269391184318" ID="CMP-001.04" LOG_CI_END="1.2951318748522833" LOG_CI_START="-0.6886307000970797" LOG_EFFECT_SIZE="0.30325058737760174" METHOD="MH" NO="4" P_CHI2="0.06255404627499839" P_Q="0.06257723429354334" P_Z="0.5490227458810095" Q="3.467730296800121" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.994215704192235" TOTALS="YES" TOTAL_1="35" TOTAL_2="35" WEIGHT="100.0" Z="0.5992251664147739">
<NAME>Adverse events: 1. Extrapyramidal</NAME>
<GROUP_LABEL_1>Penfluridol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Penfluridol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.671852101612958" CI_START="0.05351196796527171" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.6694890857160593" LOG_CI_START="-1.2715490770440216" LOG_EFFECT_SIZE="-0.3010299956639812" NO="1" P_CHI2="1.0" P_Z="0.5432337102222069" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="41.21948451738378" Z="0.6079302932701575">
<NAME>short term</NAME>
<DICH_DATA CI_END="4.671852101612958" CI_START="0.05351196796527171" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6694890857160593" LOG_CI_START="-1.2715490770440216" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="7293" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Munitz-1986" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="41.21948451738378"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.045967835812593" CI_START="1.7726848723303554" DF="0" EFFECT_SIZE="5.333333333333334" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="1.205365917322845" LOG_CI_START="0.24863153854967954" LOG_EFFECT_SIZE="0.7269987279362624" NO="2" P_CHI2="1.0" P_Z="0.002895155629085698" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="58.78051548261621" Z="2.9786560516173077">
<NAME>medium term</NAME>
<DICH_DATA CI_END="16.045967835812593" CI_START="1.7726848723303554" EFFECT_SIZE="5.333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" LOG_CI_END="1.205365917322845" LOG_CI_START="0.24863153854967954" LOG_EFFECT_SIZE="0.7269987279362623" ORDER="7294" O_E="0.0" SE="0.5619905100029122" STUDY_ID="STD-Gallant-1974" TOTAL_1="25" TOTAL_2="25" VAR="0.31583333333333335" WEIGHT="58.78051548261621"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.545955017925222" CI_END="2.194441376471777" CI_START="0.7410607498965665" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.275231105350018" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" I2="0.0" I2_Q="8.446554949904742" ID="CMP-001.05" LOG_CI_END="0.34132398335146896" LOG_CI_START="-0.13014618842632306" LOG_EFFECT_SIZE="0.10558889746257297" METHOD="MH" MODIFIED="2008-11-04 10:26:16 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.4670435320429782" P_Q="0.33545835805907565" P_Z="0.3800012118984831" Q="2.1845163760966733" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="62" TOTAL_2="60" WEIGHT="300.0" Z="0.8778940793373169">
<NAME>Adverse events: 2. Other side effects (medium term)</NAME>
<GROUP_LABEL_1>Penfluridol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Penfluridol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.16183484097002765" CI_END="1.9081506415370155" CI_START="0.5677967568055557" DF="1" EFFECT_SIZE="1.040885078075941" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.280612657687656" LOG_CI_START="-0.24580709244678273" LOG_EFFECT_SIZE="0.017402782620436628" NO="1" P_CHI2="0.6874730292482081" P_Z="0.8968924402787621" STUDIES="2" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0" Z="0.12958794634177204">
<NAME>needing antiparkinson medication</NAME>
<DICH_DATA CI_END="2.65606718850822" CI_START="0.5124535693223857" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4242390568515887" LOG_CI_START="-0.2903454775903623" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="7295" O_E="0.0" SE="0.4197504927816955" STUDY_ID="STD-Channabasavanna-1987" TOTAL_1="15" TOTAL_2="15" VAR="0.17619047619047623" WEIGHT="54.269662921348306"/>
<DICH_DATA CI_END="2.2275714500608683" CI_START="0.3710077541930935" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.34783164306559344" LOG_CI_START="-0.43061701338204356" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="7296" O_E="0.0" SE="0.4572645941803379" STUDY_ID="STD-Vandecasteele-1974" TOTAL_1="11" TOTAL_2="10" VAR="0.20909090909090908" WEIGHT="45.73033707865169"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.157917250400065" CI_START="0.3356821151045378" DF="0" EFFECT_SIZE="2.727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="1.3455289361480922" LOG_CI_START="-0.4740717970252174" LOG_EFFECT_SIZE="0.43572856956143735" NO="2" P_CHI2="1.0" P_Z="0.34789457082665587" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="100.0" Z="0.9386809840268753">
<NAME>insomnia</NAME>
<DICH_DATA CI_END="22.157917250400065" CI_START="0.3356821151045378" EFFECT_SIZE="2.727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3455289361480922" LOG_CI_START="-0.4740717970252174" LOG_EFFECT_SIZE="0.43572856956143735" ORDER="7297" O_E="0.0" SE="1.068842477834897" STUDY_ID="STD-Vandecasteele-1974" TOTAL_1="11" TOTAL_2="10" VAR="1.1424242424242423" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.461454884839547" CI_START="0.668575579459536" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="1.1290920000300073" LOG_CI_START="-0.17484949059068242" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-11-04 10:26:16 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.15147842967065045" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="1.4343288901160178">
<NAME>alterations in ECG</NAME>
<DICH_DATA CI_END="13.461454884839547" CI_START="0.668575579459536" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1290920000300073" LOG_CI_START="-0.17484949059068242" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="7298" O_E="0.0" SE="0.7659416862050704" STUDY_ID="STD-Gallant-1974" TOTAL_1="25" TOTAL_2="25" VAR="0.5866666666666666" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>PENFLURIDOL versus TYPICAL ANTIPSYCHOTICS (ORAL)</NAME>
<DICH_OUTCOME CHI2="0.08461866908200455" CI_END="1.2403650491008669" CI_START="0.6826325028757192" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9201703635454084" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.09354952022532982" LOG_CI_START="-0.1658130370601487" LOG_EFFECT_SIZE="-0.036131758417409454" METHOD="MH" NO="1" P_CHI2="0.7711332571637393" P_Q="1.0" P_Z="0.5850078086176475" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.5460845693179742">
<NAME>Global state: 1. No marked improvement (CGI)</NAME>
<GROUP_LABEL_1>Penfluridol</GROUP_LABEL_1>
<GROUP_LABEL_2>Typical AP ORAL</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Penfluridol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fav. typical AP oral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.08461866908200455" CI_END="1.2403650491008669" CI_START="0.6826325028757192" DF="1" EFFECT_SIZE="0.9201703635454084" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.09354952022532982" LOG_CI_START="-0.1658130370601487" LOG_EFFECT_SIZE="-0.036131758417409454" NO="1" P_CHI2="0.7711332571637393" P_Z="0.5850078086176475" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.5460845693179742">
<NAME>medium-term</NAME>
<DICH_DATA CI_END="1.5092914870493168" CI_START="0.6160817487902037" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.17877312247413057" LOG_CI_START="-0.21036165684059438" LOG_EFFECT_SIZE="-0.015794267183231903" ORDER="7299" O_E="0.0" SE="0.22857969561769315" STUDY_ID="STD-Charalampous-1977" TOTAL_1="28" TOTAL_2="27" VAR="0.05224867724867725" WEIGHT="44.42367294731146"/>
<DICH_DATA CI_END="1.3230160318235984" CI_START="0.5938253785064641" EFFECT_SIZE="0.8863636363636364" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.12156510684081824" LOG_CI_START="-0.22634124576019476" LOG_EFFECT_SIZE="-0.05238806945968823" ORDER="7300" O_E="0.0" SE="0.20436191368205514" STUDY_ID="STD-Donlon-1978" TOTAL_1="12" TOTAL_2="13" VAR="0.04176379176379176" WEIGHT="55.57632705268855"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3338899583668629" CI_END="1.673808224046464" CI_START="0.9033650590346947" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2296584343338972" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.22370569737916332" LOG_CI_START="-0.04413671138574785" LOG_EFFECT_SIZE="0.08978449299670774" METHOD="MH" NO="2" P_CHI2="0.8555999710410604" P_Q="0.48295718630821394" P_Z="0.18884140453648174" Q="0.4921784839845569" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="96" TOTAL_2="99" WEIGHT="200.0" Z="1.3140142627539682">
<NAME>Global state: 2. Needing additional antypsychotic</NAME>
<GROUP_LABEL_1>Penfluridol</GROUP_LABEL_1>
<GROUP_LABEL_2>Typical AP ORAL</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Penfluridol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fav. typical AP oral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.06762738968674753" CI_END="2.0101243079658477" CI_START="0.9029008327082364" DF="1" EFFECT_SIZE="1.3471981708380663" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.303222915427608" LOG_CI_START="-0.044359946444656635" LOG_EFFECT_SIZE="0.12943148449147568" NO="1" P_CHI2="0.794823152661827" P_Z="0.14437618655525206" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="47" WEIGHT="100.0" Z="1.4596867446362973">
<NAME>short-term</NAME>
<DICH_DATA CI_END="2.033878570981076" CI_START="0.9055785143581294" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.3083250205989763" LOG_CI_START="-0.04307389004979437" LOG_EFFECT_SIZE="0.13262556527459096" ORDER="7301" O_E="0.0" SE="0.20641345956774915" STUDY_ID="STD-Chouinard-1976" TOTAL_1="14" TOTAL_2="19" VAR="0.042606516290726815" WEIGHT="97.83987468644226"/>
<DICH_DATA CI_END="14.696930580691841" CI_START="0.06342981197893298" EFFECT_SIZE="0.9655172413793104" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.167226642839416" LOG_CI_START="-1.1977065759528895" LOG_EFFECT_SIZE="-0.015239966556736846" ORDER="7302" O_E="0.0" SE="1.389173479326835" STUDY_ID="STD-Jacobsson-1976" TOTAL_1="29" TOTAL_2="28" VAR="1.9298029556650245" WEIGHT="2.160125313557744"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6680983718944054" CI_END="1.7456321232518097" CI_START="0.663284515290955" DF="2" EFFECT_SIZE="1.0760347377047812" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.24195272523707012" LOG_CI_START="-0.17830014140536232" LOG_EFFECT_SIZE="0.03182629191585391" NO="2" P_CHI2="0.7160186321117525" P_Z="0.7665724770340395" STUDIES="3" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="0.2968612036600618">
<NAME>medium-term</NAME>
<DICH_DATA CI_END="5.168439884619927" CI_START="0.4036846320482742" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7133594692542911" LOG_CI_START="-0.39395778351926725" LOG_EFFECT_SIZE="0.15970084286751188" ORDER="7303" O_E="0.0" SE="0.6504436355879908" STUDY_ID="STD-Donlon-1978" TOTAL_1="12" TOTAL_2="13" VAR="0.423076923076923" WEIGHT="14.403805089949323"/>
<DICH_DATA CI_END="2.3571874226469345" CI_START="0.5982367954502771" EFFECT_SIZE="1.1875" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.3723941151443037" LOG_CI_START="-0.22312687855049534" LOG_EFFECT_SIZE="0.07463361829690418" ORDER="7304" O_E="0.0" SE="0.3498119795727865" STUDY_ID="STD-Jus-1974" TOTAL_1="20" TOTAL_2="19" VAR="0.12236842105263157" WEIGHT="49.79975622496953"/>
<DICH_DATA CI_END="1.8707847669884377" CI_START="0.37120488508271915" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.27202382497401284" LOG_CI_START="-0.43038631706926245" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="7305" O_E="0.0" SE="0.41259919442249915" STUDY_ID="STD-Wang-1982" TOTAL_1="21" TOTAL_2="20" VAR="0.17023809523809524" WEIGHT="35.79643868508116"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.883577805586456" CI_START="-4.403577805586452" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.240000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.6667295094702888" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="0.43064088501161724">
<NAME>Mental state: 1. BPRS mean endpoint score</NAME>
<GROUP_LABEL_1>Penfluridol</GROUP_LABEL_1>
<GROUP_LABEL_2>Fluphenazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Penfluridol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Fluphenazine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.883577805586456" CI_START="-4.403577805586452" DF="0" EFFECT_SIZE="1.240000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" NO="1" P_CHI2="1.0" P_Z="0.6667295094702888" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0" Z="0.43064088501161724">
<NAME>medium-term</NAME>
<CONT_DATA CI_END="6.883577805586456" CI_START="-4.403577805586452" EFFECT_SIZE="1.240000000000002" ESTIMABLE="YES" MEAN_1="30.1" MEAN_2="28.86" ORDER="7306" SD_1="10.74" SD_2="7.28" SE="2.879429341611517" STUDY_ID="STD-Lapierre-1978" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="8.63481062904672" CI_END="1.4818556975498784" CI_START="0.7617719193685442" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.062466968404093" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="54" I2="7.351760870253193" I2_Q="61.197283535736645" ID="CMP-002.04" LOG_CI_END="0.170805914298444" LOG_CI_START="-0.1181750404543576" LOG_EFFECT_SIZE="0.02631543692204326" METHOD="MH" NO="4" P_CHI2="0.3740328736454539" P_Q="0.10841782309751546" P_Z="0.7211218148881273" Q="2.577139157050984" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.01726927861435228" TOTALS="SUB" TOTAL_1="178" TOTAL_2="175" WEIGHT="200.0" Z="0.3569599155678634">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Penfluridol</GROUP_LABEL_1>
<GROUP_LABEL_2>Typical AP ORAL</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Penfluridol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fav. typical AP oral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7736213995644003" CI_END="1.346202096663859" CI_START="0.15917884073971322" DF="2" EFFECT_SIZE="0.4629113188811918" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.12911026262009964" LOG_CI_START="-0.7981146624822426" LOG_EFFECT_SIZE="-0.33450219993107144" NO="1" P_CHI2="0.6792198426170568" P_Z="0.15732122051492065" STUDIES="3" TAU2="0.0" TOTAL_1="57" TOTAL_2="61" WEIGHT="99.99999999999999" Z="1.4141385695427757">
<NAME>short-term</NAME>
<DICH_DATA CI_END="2.5458628225710256" CI_START="0.00862099623166689" EFFECT_SIZE="0.14814814814814814" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.40583499907983145" LOG_CI_START="-2.0644425447418815" LOG_EFFECT_SIZE="-0.829303772831025" ORDER="7307" O_E="0.0" SE="1.4510532573119277" STUDY_ID="STD-Chouinard-1976" TOTAL_1="14" TOTAL_2="19" VAR="2.1055555555555556" WEIGHT="14.088952154239168"/>
<DICH_DATA CI_END="4.904444147473397" CI_START="0.05097417617219506" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6905897930891655" LOG_CI_START="-1.2926497844171279" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="7308" O_E="0.0" SE="1.164964745021435" STUDY_ID="STD-D_x0027_Elia-1977" TOTAL_1="14" TOTAL_2="14" VAR="1.3571428571428572" WEIGHT="21.85847372233714"/>
<DICH_DATA CI_END="2.198816468456296" CI_START="0.15262777973455377" EFFECT_SIZE="0.5793103448275863" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3421889810374218" LOG_CI_START="-0.8163664133836082" LOG_EFFECT_SIZE="-0.2370887161730932" ORDER="7309" O_E="0.0" SE="0.6805411736246073" STUDY_ID="STD-Jacobsson-1976" TOTAL_1="29" TOTAL_2="28" VAR="0.46313628899835796" WEIGHT="64.05257412342368"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.184876713022612" CI_END="1.6489129131347937" CI_START="0.8185948656603947" DF="5" EFFECT_SIZE="1.1618053385198686" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="43" I2="19.157644816553674" ID="CMP-002.04.02" LOG_CI_END="0.2171977191110139" LOG_CI_START="-0.08693098363693985" LOG_EFFECT_SIZE="0.065133367737037" NO="2" P_CHI2="0.28864314513902023" P_Z="0.4011849907942082" STUDIES="6" TAU2="0.03663015484366072" TOTAL_1="121" TOTAL_2="114" WEIGHT="100.0" Z="0.8395067864554236">
<NAME>medium-term</NAME>
<DICH_DATA CI_END="1.7141205744810182" CI_START="0.6967635488859849" EFFECT_SIZE="1.0928571428571427" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.23404136775637466" LOG_CI_START="-0.15691457747765314" LOG_EFFECT_SIZE="0.03856339513936073" ORDER="7310" O_E="0.0" SE="0.22964945749360835" STUDY_ID="STD-Charalampous-1977" TOTAL_1="28" TOTAL_2="27" VAR="0.052738873327108624" WEIGHT="35.711080251564205"/>
<DICH_DATA CI_END="1.4176980055556325" CI_START="0.6291715902445578" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.15158372838663545" LOG_CI_START="-0.20123089583669973" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="7311" O_E="0.0" SE="0.20724505672934357" STUDY_ID="STD-Claghorn-1979" TOTAL_1="28" TOTAL_2="28" VAR="0.04295051353874883" WEIGHT="40.10351511091461"/>
<DICH_DATA CI_END="39.96536195131041" CI_START="0.7341426761885176" EFFECT_SIZE="5.416666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6016837505661237" LOG_CI_START="-0.1342195293756622" LOG_EFFECT_SIZE="0.7337321105952308" ORDER="7312" O_E="0.0" SE="1.0196781794976246" STUDY_ID="STD-Donlon-1978" TOTAL_1="12" TOTAL_2="13" VAR="1.0397435897435898" WEIGHT="2.965015221766167"/>
<DICH_DATA CI_END="5.589897580584607" CI_START="0.7155766169836816" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7474038507138955" LOG_CI_START="-0.14534385938593308" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="7313" O_E="0.0" SE="0.5244044240850758" STUDY_ID="STD-Lapierre-1978" TOTAL_1="20" TOTAL_2="20" VAR="0.275" WEIGHT="10.24119292502918"/>
<DICH_DATA CI_END="77.60910025685016" CI_START="0.302608934040809" EFFECT_SIZE="4.846153846153846" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.8899126485727842" LOG_CI_START="-0.5191182542792946" LOG_EFFECT_SIZE="0.6853971971467449" ORDER="7314" O_E="0.0" SE="1.4150766772306025" STUDY_ID="STD-Ota-1974" TOTAL_1="12" TOTAL_2="6" VAR="2.0024420024420024" WEIGHT="1.5651552720228423"/>
<DICH_DATA CI_END="2.7982042975421706" CI_START="0.3241469821394912" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.44687941925381636" LOG_CI_START="-0.4892580173936927" LOG_EFFECT_SIZE="-0.021189299069938095" ORDER="7315" O_E="0.0" SE="0.5498917642417936" STUDY_ID="STD-Wang-1982" TOTAL_1="21" TOTAL_2="20" VAR="0.3023809523809524" WEIGHT="9.414041218702987"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.970626379172439" CI_END="1.5549499935982538" CI_START="0.6363388504560995" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9947236256584199" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="39" I2="39.64543357009523" I2_Q="27.7315173932405" ID="CMP-002.05" LOG_CI_END="0.19171642689755314" LOG_CI_START="-0.19631156093219848" LOG_EFFECT_SIZE="-0.0022975670173226337" METHOD="MH" NO="5" P_CHI2="0.17396086421438217" P_Q="0.2506423992832807" P_Z="0.9814824173435597" Q="2.7674581336967683" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.09712175385538346" TOTALS="SUB" TOTAL_1="86" TOTAL_2="94" WEIGHT="300.0" Z="0.023210431965001922">
<NAME>Adverse events (short term)</NAME>
<GROUP_LABEL_1>Penfluridol</GROUP_LABEL_1>
<GROUP_LABEL_2>Typical AP ORAL</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Penfluridol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fav. typical AP oral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9532172557229939" CI_END="1.9676092897640727" CI_START="0.6089442572893145" DF="1" EFFECT_SIZE="1.0946069511888452" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" I2="48.80241831419595" ID="CMP-002.05.01" LOG_CI_END="0.29393886434661004" LOG_CI_START="-0.21542246083125746" LOG_EFFECT_SIZE="0.039258201757676324" NO="1" P_CHI2="0.16224087456501124" P_Z="0.7625589714711593" STUDIES="2" TAU2="0.08838404833341904" TOTAL_1="43" TOTAL_2="47" WEIGHT="99.99999999999999" Z="0.3021221193657909">
<NAME>needing antiparkinsonism medication</NAME>
<DICH_DATA CI_END="2.9424521609352015" CI_START="0.7922217558181307" EFFECT_SIZE="1.5267857142857142" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4687094107131773" LOG_CI_START="-0.10115323526923298" LOG_EFFECT_SIZE="0.1837780877219722" ORDER="7316" O_E="0.0" SE="0.33474013911565975" STUDY_ID="STD-Chouinard-1976" TOTAL_1="14" TOTAL_2="19" VAR="0.11205096073517126" WEIGHT="44.66358272889598"/>
<DICH_DATA CI_END="1.4230228604380981" CI_START="0.4920535579253304" EFFECT_SIZE="0.8367816091954023" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.15321187695172847" LOG_CI_START="-0.3079876235628911" LOG_EFFECT_SIZE="-0.07738787330558132" ORDER="7317" O_E="0.0" SE="0.2709108695766344" STUDY_ID="STD-Jacobsson-1976" TOTAL_1="29" TOTAL_2="28" VAR="0.07339269925476821" WEIGHT="55.336417271104004"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2389583070441006" CI_START="0.5140306810702043" DF="0" EFFECT_SIZE="1.0727969348659003" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.35004600640204453" LOG_CI_START="-0.2890109583941681" LOG_EFFECT_SIZE="0.03051752400393824" NO="2" P_CHI2="1.0" P_Z="0.8515099198199803" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0" Z="0.1871922261707272">
<NAME>insomnia</NAME>
<DICH_DATA CI_END="2.2389583070441006" CI_START="0.5140306810702043" EFFECT_SIZE="1.0727969348659003" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.35004600640204453" LOG_CI_START="-0.2890109583941681" LOG_EFFECT_SIZE="0.03051752400393824" ORDER="7318" O_E="0.0" SE="0.3753852245042894" STUDY_ID="STD-Jacobsson-1976" TOTAL_1="29" TOTAL_2="28" VAR="0.14091406677613577" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4018186646971733" CI_START="0.026814099238570907" DF="0" EFFECT_SIZE="0.19387755102040813" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" ID="CMP-002.05.03" LOG_CI_END="0.1466918381564601" LOG_CI_START="-1.571636787635792" LOG_EFFECT_SIZE="-0.712472474739666" NO="3" P_CHI2="1.0" P_Z="0.10409353703518688" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="19" WEIGHT="100.0" Z="1.6253240148659407">
<NAME>drowsiness</NAME>
<DICH_DATA CI_END="1.4018186646971733" CI_START="0.026814099238570907" EFFECT_SIZE="0.19387755102040816" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.1466918381564601" LOG_CI_START="-1.571636787635792" LOG_EFFECT_SIZE="-0.7124724747396659" ORDER="7319" O_E="0.0" SE="1.0093547406542474" STUDY_ID="STD-Chouinard-1976" TOTAL_1="14" TOTAL_2="19" VAR="1.018796992481203" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.356865299966774" CI_END="1.4285384413484832" CI_START="0.9894519544579499" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1888945086972897" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="142" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.1548919315517302" LOG_CI_START="-0.004605289300318573" LOG_EFFECT_SIZE="0.0751433211257058" METHOD="MH" NO="6" P_CHI2="0.6725515475573086" P_Q="0.9807333805574929" P_Z="0.06477891469821881" Q="4.142105450226651" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="497" TOTAL_2="517" WEIGHT="1300.0" Z="1.8467808065662523">
<NAME>Adverse events (medium term)</NAME>
<GROUP_LABEL_1>Penfluridol</GROUP_LABEL_1>
<GROUP_LABEL_2>Typical AP ORAL</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Penfluridol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fav. typical AP oral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4194479986072586" CI_END="1.5813247887422945" CI_START="0.9128881944930797" DF="3" EFFECT_SIZE="1.2014877158348745" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="40" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.19902107895941645" LOG_CI_START="-0.0395824091995975" LOG_EFFECT_SIZE="0.0797193348799095" NO="1" P_CHI2="0.700982429213254" P_Z="0.19030434752474149" STUDIES="4" TAU2="0.0" TOTAL_1="84" TOTAL_2="85" WEIGHT="100.0" Z="1.3096793047047295">
<NAME>needing antiparkinsonism medication</NAME>
<DICH_DATA CI_END="1.6460871745451402" CI_START="0.7818452159095882" EFFECT_SIZE="1.134453781512605" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.21645283113227" LOG_CI_START="-0.10687921692731937" LOG_EFFECT_SIZE="0.05478680710247535" ORDER="7320" O_E="0.0" SE="0.18992684554965356" STUDY_ID="STD-Charalampous-1977" TOTAL_1="28" TOTAL_2="27" VAR="0.03607220666044196" WEIGHT="54.45729563312984"/>
<DICH_DATA CI_END="2.4728576680132095" CI_START="0.36070628737747895" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.39319912009143765" LOG_CI_START="-0.442846287541502" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="7321" O_E="0.0" SE="0.4910972109351012" STUDY_ID="STD-Khorana-1988" TOTAL_1="15" TOTAL_2="17" VAR="0.24117647058823533" WEIGHT="8.145051701999932"/>
<DICH_DATA CI_END="2.2566507890618626" CI_START="0.4885558746368253" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.35346435831685097" LOG_CI_START="-0.3110857601769747" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="7322" O_E="0.0" SE="0.3903600291794133" STUDY_ID="STD-Lapierre-1978" TOTAL_1="20" TOTAL_2="21" VAR="0.1523809523809524" WEIGHT="12.891341020996219"/>
<DICH_DATA CI_END="2.764740222948715" CI_START="0.9113067145103978" EFFECT_SIZE="1.5873015873015872" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.4416543309246065" LOG_CI_START="-0.04033542983177003" LOG_EFFECT_SIZE="0.20065945054641826" ORDER="7323" O_E="0.0" SE="0.28312317135609044" STUDY_ID="STD-Wang-1982" TOTAL_1="21" TOTAL_2="20" VAR="0.08015873015873014" WEIGHT="24.50631164387401"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.470019149679551" CI_END="10.56505921648239" CI_START="0.43394121225223437" DF="1" EFFECT_SIZE="2.141171315872929" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" I2="59.51448392091473" ID="CMP-002.06.02" LOG_CI_END="1.023871935587998" LOG_CI_START="-0.362569102109117" LOG_EFFECT_SIZE="0.33065141673944043" NO="2" P_CHI2="0.11603676175013433" P_Z="0.3498599189246038" STUDIES="2" TAU2="0.8863179184558357" TOTAL_1="43" TOTAL_2="45" WEIGHT="100.0" Z="0.9348610588199069">
<NAME>insomnia</NAME>
<DICH_DATA CI_END="46.662124737707416" CI_START="0.7715036596031511" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6689645103011272" LOG_CI_START="-0.11266200953384008" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="7324" O_E="0.0" SE="1.0465362369445672" STUDY_ID="STD-Claghorn-1979" TOTAL_1="28" TOTAL_2="28" VAR="1.0952380952380951" WEIGHT="33.47122908174863"/>
<DICH_DATA CI_END="2.4469069651686404" CI_START="0.6643591371231239" EFFECT_SIZE="1.275" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3886174571809708" LOG_CI_START="-0.17759708764102292" LOG_EFFECT_SIZE="0.10551018476997394" ORDER="7325" O_E="0.0" SE="0.33259722643563905" STUDY_ID="STD-Khorana-1988" TOTAL_1="15" TOTAL_2="17" VAR="0.11062091503267975" WEIGHT="66.52877091825137"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.625882191752627" CI_END="3.411989832917657" CI_START="0.481666227834432" DF="3" EFFECT_SIZE="1.2819673444479316" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" I2="35.14750536992431" ID="CMP-002.06.03" LOG_CI_END="0.5330077283822564" LOG_CI_START="-0.31725380330011616" LOG_EFFECT_SIZE="0.10787696254107013" NO="3" P_CHI2="0.20133305373146793" P_Z="0.6189486037688933" STUDIES="4" TAU2="0.3454698738393147" TOTAL_1="75" TOTAL_2="79" WEIGHT="100.0" Z="0.4973410026529546">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="159.695948345656" CI_START="0.507213870101942" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.203293897770007" LOG_CI_START="-0.29480887889135743" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="7326" O_E="0.0" SE="1.4673979368190633" STUDY_ID="STD-Claghorn-1979" TOTAL_1="28" TOTAL_2="28" VAR="2.1532567049808433" WEIGHT="9.983010529280824"/>
<DICH_DATA CI_END="27.152416069598246" CI_START="0.38900773960319934" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4338084799288948" LOG_CI_START="-0.410041757971146" LOG_EFFECT_SIZE="0.5118833609788743" ORDER="7327" O_E="0.0" SE="1.0830867569483633" STUDY_ID="STD-Donlon-1978" TOTAL_1="12" TOTAL_2="13" VAR="1.1730769230769231" WEIGHT="16.42676656182854"/>
<DICH_DATA CI_END="3.164706960656527" CI_START="0.405865206609203" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5003335022643364" LOG_CI_START="-0.3916181776191511" LOG_EFFECT_SIZE="0.054357662322592676" ORDER="7328" O_E="0.0" SE="0.5239368319955838" STUDY_ID="STD-Khorana-1988" TOTAL_1="15" TOTAL_2="17" VAR="0.27450980392156865" WEIGHT="40.23488936967434"/>
<DICH_DATA CI_END="1.8201462057237174" CI_START="0.15143014288261936" EFFECT_SIZE="0.525" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2601062746821901" LOG_CI_START="-0.8197876678702763" LOG_EFFECT_SIZE="-0.2798406965940431" ORDER="7329" O_E="0.0" SE="0.6343350474165466" STUDY_ID="STD-Lapierre-1978" TOTAL_1="20" TOTAL_2="21" VAR="0.4023809523809524" WEIGHT="33.35533353921629"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.25132343138079494" CI_END="13.517023225759878" CI_START="0.23233041377615093" DF="1" EFFECT_SIZE="1.7721217788466554" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.06.04" LOG_CI_END="1.1308810600251147" LOG_CI_START="-0.6338939341060461" LOG_EFFECT_SIZE="0.24849356295953426" NO="4" P_CHI2="0.6161447812612365" P_Z="0.5809789985259162" STUDIES="2" TAU2="0.0" TOTAL_1="27" TOTAL_2="30" WEIGHT="100.0" Z="0.5519552752168317">
<NAME>acute dystonia</NAME>
<DICH_DATA CI_END="72.45938986445702" CI_START="0.14405130711161593" EFFECT_SIZE="3.230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.86009467278967" LOG_CI_START="-0.8414827966075424" LOG_EFFECT_SIZE="0.5093059380910637" ORDER="7330" O_E="0.0" SE="1.5869199785480734" STUDY_ID="STD-Donlon-1978" TOTAL_1="12" TOTAL_2="13" VAR="2.518315018315018" WEIGHT="42.67208185568325"/>
<DICH_DATA CI_END="16.58673887610161" CI_START="0.07743803372313825" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2197610076438197" LOG_CI_START="-1.1110456829986344" LOG_EFFECT_SIZE="0.054357662322592676" ORDER="7331" O_E="0.0" SE="1.3691273877625736" STUDY_ID="STD-Khorana-1988" TOTAL_1="15" TOTAL_2="17" VAR="1.8745098039215686" WEIGHT="57.32791814431674"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0652266013342846" CI_START="0.5703563985048459" DF="0" EFFECT_SIZE="1.3222222222222222" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-002.06.05" LOG_CI_END="0.4864625858924005" LOG_CI_START="-0.24385368198598872" LOG_EFFECT_SIZE="0.12130445195320587" NO="5" P_CHI2="1.0" P_Z="0.5149856597585585" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.00000000000001" Z="0.6510942380712325">
<NAME>lack of facial expression</NAME>
<DICH_DATA CI_END="3.0652266013342846" CI_START="0.5703563985048459" EFFECT_SIZE="1.3222222222222222" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4864625858924005" LOG_CI_START="-0.24385368198598872" LOG_EFFECT_SIZE="0.12130445195320587" ORDER="7332" O_E="0.0" SE="0.42899139087559574" STUDY_ID="STD-Khorana-1988" TOTAL_1="15" TOTAL_2="17" VAR="0.18403361344537816" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.18324503042000884" CI_END="2.1545445866341173" CI_START="0.48122746260530924" DF="1" EFFECT_SIZE="1.0182465440628516" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" ID="CMP-002.06.06" LOG_CI_END="0.3333554859058457" LOG_CI_START="-0.31764959638286183" LOG_EFFECT_SIZE="0.00785294476149187" NO="6" P_CHI2="0.668599223731221" P_Z="0.9622858350703901" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="100.0" Z="0.04728531104855743">
<NAME>drowsiness</NAME>
<DICH_DATA CI_END="3.480876014725685" CI_START="0.41368896619935513" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5416885544306737" LOG_CI_START="-0.383326062335424" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="7333" O_E="0.0" SE="0.5433581647846062" STUDY_ID="STD-Claghorn-1979" TOTAL_1="28" TOTAL_2="28" VAR="0.2952380952380953" WEIGHT="49.530369442705066"/>
<DICH_DATA CI_END="2.4890605496092" CI_START="0.30176490131147704" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.39603546151068564" LOG_CI_START="-0.5203312750083746" LOG_EFFECT_SIZE="-0.06214790674884446" ORDER="7334" O_E="0.0" SE="0.5382783571197989" STUDY_ID="STD-Donlon-1978" TOTAL_1="12" TOTAL_2="13" VAR="0.28974358974358977" WEIGHT="50.46963055729493"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.370171431963174" CI_START="0.2685503599532479" DF="0" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-002.06.07" LOG_CI_END="0.6404984736970393" LOG_CI_START="-0.5709742611786154" LOG_EFFECT_SIZE="0.03476210625921191" NO="7" P_CHI2="1.0" P_Z="0.910443808896551" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.11247876131822784">
<NAME>nausea</NAME>
<DICH_DATA CI_END="4.370171431963174" CI_START="0.2685503599532479" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6404984736970393" LOG_CI_START="-0.5709742611786154" LOG_EFFECT_SIZE="0.03476210625921191" ORDER="7335" O_E="0.0" SE="0.7116250813527137" STUDY_ID="STD-Donlon-1978" TOTAL_1="12" TOTAL_2="13" VAR="0.5064102564102564" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.836822293440772" CI_END="1.6623591841320757" CI_START="0.44160768466960715" DF="2" EFFECT_SIZE="0.856802538741467" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="34" I2="65.73477999754192" ID="CMP-002.06.08" LOG_CI_END="0.22072486712129147" LOG_CI_START="-0.3549633778047466" LOG_EFFECT_SIZE="-0.06711925534172762" NO="8" P_CHI2="0.054019534244661216" P_Z="0.6476546682708862" STUDIES="3" TAU2="0.19405820631541004" TOTAL_1="68" TOTAL_2="67" WEIGHT="100.0" Z="0.4570227872408092">
<NAME>extrapyramidal</NAME>
<DICH_DATA CI_END="1.6460871745451402" CI_START="0.7818452159095882" EFFECT_SIZE="1.134453781512605" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.21645283113227" LOG_CI_START="-0.10687921692731937" LOG_EFFECT_SIZE="0.05478680710247535" ORDER="7336" O_E="0.0" SE="0.18992684554965356" STUDY_ID="STD-Charalampous-1977" TOTAL_1="28" TOTAL_2="27" VAR="0.03607220666044196" WEIGHT="49.69079103965882"/>
<DICH_DATA CI_END="0.9007890798637157" CI_START="0.31700721845806923" EFFECT_SIZE="0.534375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="-0.045376887350273884" LOG_CI_START="-0.49893084850523023" LOG_EFFECT_SIZE="-0.2721538679277521" ORDER="7337" O_E="0.0" SE="0.2664198419107381" STUDY_ID="STD-Jus-1974" TOTAL_1="20" TOTAL_2="19" VAR="0.07097953216374268" WEIGHT="43.14616600893209"/>
<DICH_DATA CI_END="21.390976158817587" CI_START="0.2061616995530217" EFFECT_SIZE="2.1" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3302306036792753" LOG_CI_START="-0.6857920142114367" LOG_EFFECT_SIZE="0.3222192947339193" ORDER="7338" O_E="0.0" SE="1.1842216652219095" STUDY_ID="STD-Lapierre-1978" TOTAL_1="20" TOTAL_2="21" VAR="1.4023809523809523" WEIGHT="7.1630429514091"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4728576680132095" CI_START="0.36070628737747895" DF="0" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-002.06.09" LOG_CI_END="0.39319912009143765" LOG_CI_START="-0.442846287541502" LOG_EFFECT_SIZE="-0.024823583725032152" NO="9" P_CHI2="1.0" P_Z="0.9073440906193632" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="0.11638920475869319">
<NAME>fatigue</NAME>
<DICH_DATA CI_END="2.4728576680132095" CI_START="0.36070628737747895" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.39319912009143765" LOG_CI_START="-0.442846287541502" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="7339" O_E="0.0" SE="0.4910972109351012" STUDY_ID="STD-Khorana-1988" TOTAL_1="15" TOTAL_2="17" VAR="0.24117647058823533" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4171807616324532" CI_END="2.082887580322979" CI_START="0.9542821848621237" DF="2" EFFECT_SIZE="1.4098448535114758" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" I2="0.0" ID="CMP-002.06.10" LOG_CI_END="0.3186658304072119" LOG_CI_START="-0.02032318377885633" LOG_EFFECT_SIZE="0.14917132331417782" NO="10" P_CHI2="0.4923377829660881" P_Z="0.08453555726918202" STUDIES="3" TAU2="0.0" TOTAL_1="63" TOTAL_2="65" WEIGHT="100.0" Z="1.7249551400594292">
<NAME>tremors</NAME>
<DICH_DATA CI_END="27.121552448899386" CI_START="0.3318394113669268" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4333145451026126" LOG_CI_START="-0.47907203566328754" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="7340" O_E="0.0" SE="1.1233453440081378" STUDY_ID="STD-Claghorn-1979" TOTAL_1="28" TOTAL_2="28" VAR="1.2619047619047616" WEIGHT="3.1420990602405516"/>
<DICH_DATA CI_END="2.004755783805814" CI_START="0.894860181662399" EFFECT_SIZE="1.3393939393939394" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.30206147510812054" LOG_CI_START="-0.04824481616571171" LOG_EFFECT_SIZE="0.1269083294712044" ORDER="7341" O_E="0.0" SE="0.20577164953835714" STUDY_ID="STD-Khorana-1988" TOTAL_1="15" TOTAL_2="17" VAR="0.04234197175373647" WEIGHT="93.64301193989942"/>
<DICH_DATA CI_END="26.450125630660757" CI_START="0.34026303412212444" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4224277391527982" LOG_CI_START="-0.4681852297134733" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="7342" O_E="0.0" SE="1.1105554165971787" STUDY_ID="STD-Lapierre-1978" TOTAL_1="20" TOTAL_2="20" VAR="1.2333333333333332" WEIGHT="3.214888999860024"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.235701242768925" CI_START="0.05603886932681634" DF="0" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.06.11" LOG_CI_END="0.718974857069199" LOG_CI_START="-1.2515106358787376" LOG_EFFECT_SIZE="-0.2662678894047693" NO="11" P_CHI2="1.0" P_Z="0.5963253058676485" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.00000000000001" Z="0.5296922766907484">
<NAME>postural hypotension</NAME>
<DICH_DATA CI_END="5.235701242768925" CI_START="0.05603886932681634" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.718974857069199" LOG_CI_START="-1.2515106358787376" LOG_EFFECT_SIZE="-0.2662678894047693" ORDER="7343" O_E="0.0" SE="1.1574729326181195" STUDY_ID="STD-Donlon-1978" TOTAL_1="12" TOTAL_2="13" VAR="1.3397435897435899" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.769115652451022" CI_START="0.2968617232425196" DF="0" EFFECT_SIZE="0.9066666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-002.06.12" LOG_CI_END="0.44234109448606196" LOG_CI_START="-0.5274457958569895" LOG_EFFECT_SIZE="-0.04255235068546375" NO="12" P_CHI2="1.0" P_Z="0.863438498245249" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.00000000000001" Z="0.17199876721683674">
<NAME>rigidity</NAME>
<DICH_DATA CI_END="2.769115652451022" CI_START="0.2968617232425196" EFFECT_SIZE="0.9066666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.44234109448606196" LOG_CI_START="-0.5274457958569895" LOG_EFFECT_SIZE="-0.04255235068546375" ORDER="7344" O_E="0.0" SE="0.5696576199100374" STUDY_ID="STD-Khorana-1988" TOTAL_1="15" TOTAL_2="17" VAR="0.32450980392156864" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.848616069043482" CI_START="0.014156777466712338" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.06.13" LOG_CI_END="0.8947930852084158" LOG_CI_START="-1.8490355946477406" LOG_EFFECT_SIZE="-0.47712125471966244" NO="13" P_CHI2="1.0" P_Z="0.49547179043695244" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="99.99999999999999" Z="0.6816318251751228">
<NAME>muscle spasm</NAME>
<DICH_DATA CI_END="7.848616069043482" CI_START="0.014156777466712338" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8947930852084158" LOG_CI_START="-1.8490355946477406" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="7345" O_E="0.0" SE="1.611738548718522" STUDY_ID="STD-Claghorn-1979" TOTAL_1="28" TOTAL_2="28" VAR="2.5977011494252875" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>PENFLURIDOL versus TYPICAL ANTIPSYCHOTICS (DEPOT)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.288930488946035" CI_START="0.15727869489202628" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.35963260406574094" LOG_CI_START="-0.8033301032984537" LOG_EFFECT_SIZE="-0.2218487496163564" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.45459761212847993" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.00000000000001" Z="0.7477721452458155">
<NAME>Global state: 1. No marked improvment (CGI)</NAME>
<GROUP_LABEL_1>Penfluridol</GROUP_LABEL_1>
<GROUP_LABEL_2>Fluphenazine DEPOT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours penfluridol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fluphenazine depot</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.288930488946035" CI_START="0.15727869489202628" DF="0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.35963260406574094" LOG_CI_START="-0.8033301032984537" LOG_EFFECT_SIZE="-0.2218487496163564" NO="1" P_CHI2="1.0" P_Z="0.45459761212847993" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.00000000000001" Z="0.7477721452458155">
<NAME>medium-term</NAME>
<DICH_DATA CI_END="2.288930488946035" CI_START="0.15727869489202628" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.35963260406574094" LOG_CI_START="-0.8033301032984537" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="7346" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Ionescu-1983" TOTAL_1="30" TOTAL_2="30" VAR="0.4666666666666667" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6165737731803149" CI_END="1.936730371313532" CI_START="0.23304015781146625" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6718154146558153" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.28706916310349967" LOG_CI_START="-0.6325692342822696" LOG_EFFECT_SIZE="-0.172750035589385" METHOD="MH" NO="2" P_CHI2="0.43232354524313954" P_Q="1.0" P_Z="0.4615230482196685" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="47" TOTAL_2="51" WEIGHT="100.00000000000001" Z="0.736341259881471">
<NAME>Global state: 2. Needing additional antipsychotic</NAME>
<GROUP_LABEL_1>Penfluridol</GROUP_LABEL_1>
<GROUP_LABEL_2>Typical AP DEPOT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Penfluridol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Typical AP depot</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6165737731803149" CI_END="1.936730371313532" CI_START="0.23304015781146625" DF="1" EFFECT_SIZE="0.6718154146558153" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.28706916310349967" LOG_CI_START="-0.6325692342822696" LOG_EFFECT_SIZE="-0.172750035589385" NO="1" P_CHI2="0.43232354524313954" P_Z="0.4615230482196685" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="51" WEIGHT="100.00000000000001" Z="0.736341259881471">
<NAME>medium-term</NAME>
<DICH_DATA CI_END="1.816767939244651" CI_START="0.1376070078074701" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2592994572244536" LOG_CI_START="-0.861359448552416" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="7347" O_E="0.0" SE="0.6582805886043833" STUDY_ID="STD-Ionescu-1983" TOTAL_1="30" TOTAL_2="30" VAR="0.43333333333333335" WEIGHT="67.3421997044543"/>
<DICH_DATA CI_END="7.877630092708226" CI_START="0.19370693205128953" EFFECT_SIZE="1.2352941176470589" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8963955839283987" LOG_CI_START="-0.7128548372171079" LOG_EFFECT_SIZE="0.09177037335564536" ORDER="7348" O_E="0.0" SE="0.9452816632989278" STUDY_ID="STD-Iqbal-1978" TOTAL_1="17" TOTAL_2="21" VAR="0.8935574229691876" WEIGHT="32.65780029554571"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.25456940268931927" CI_START="-5.454569402689319" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.5999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.07423291149205741" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.7851751493599122">
<NAME>Mental state: 1. BPRS mean endpoint score</NAME>
<GROUP_LABEL_1>Penfluridol</GROUP_LABEL_1>
<GROUP_LABEL_2>Fluphenazine DEPOT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Penfluridol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fluphenazine depot</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.25456940268931927" CI_START="-5.454569402689319" DF="0" EFFECT_SIZE="-2.5999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.01" NO="1" P_CHI2="1.0" P_Z="0.07423291149205741" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.7851751493599122">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.25456940268931927" CI_START="-5.454569402689319" EFFECT_SIZE="-2.5999999999999996" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="13.6" ORDER="7349" SD_1="5.38" SD_2="5.89" SE="1.456439722977462" STUDY_ID="STD-Ionescu-1983" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.4905650466250036" CI_END="0.9711242955348531" CI_START="0.3126230735981985" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5509953376535877" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="34" I2="10.924350088051836" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-0.012725180586102298" LOG_CI_START="-0.504978971401385" LOG_EFFECT_SIZE="-0.25885207599374366" METHOD="MH" NO="4" P_CHI2="0.34366780566263655" P_Q="1.0" P_Z="0.03927466964656319" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.05489189628573795" TOTALS="SUB" TOTAL_1="110" TOTAL_2="108" WEIGHT="100.0" Z="2.0612974678402884">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Penfluridol</GROUP_LABEL_1>
<GROUP_LABEL_2>Typical AP DEPOT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Typical AP depot</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.4905650466250036" CI_END="0.9711242955348531" CI_START="0.3126230735981985" DF="4" EFFECT_SIZE="0.5509953376535877" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="34" I2="10.924350088051836" ID="CMP-003.04.01" LOG_CI_END="-0.012725180586102298" LOG_CI_START="-0.504978971401385" LOG_EFFECT_SIZE="-0.25885207599374366" NO="1" P_CHI2="0.34366780566263655" P_Z="0.03927466964656319" STUDIES="5" TAU2="0.05489189628573795" TOTAL_1="110" TOTAL_2="108" WEIGHT="100.0" Z="2.0612974678402884">
<NAME>medium-term</NAME>
<DICH_DATA CI_END="0.9355805736212024" CI_START="0.05468490150586312" EFFECT_SIZE="0.2261904761904762" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.028918804452351236" LOG_CI_START="-1.262132565765754" LOG_EFFECT_SIZE="-0.6455256851090527" ORDER="7350" O_E="0.0" SE="0.7243958679020636" STUDY_ID="STD-Doongaji-1988" TOTAL_1="21" TOTAL_2="19" VAR="0.524749373433584" WEIGHT="14.424276655954776"/>
<DICH_DATA CI_END="3.0260386806300987" CI_START="0.036718338011454264" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48087447513357967" LOG_CI_START="-1.4351169845729046" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="7351" O_E="0.0" SE="1.1254628677422753" STUDY_ID="STD-Gerlach-1975" TOTAL_1="30" TOTAL_2="30" VAR="1.2666666666666664" WEIGHT="6.326549779952141"/>
<DICH_DATA CI_END="2.9494641286495895" CI_START="0.19071260929609624" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4697431186525557" LOG_CI_START="-0.7196205918691555" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="7352" O_E="0.0" SE="0.6986381310057718" STUDY_ID="STD-Iqbal-1978" TOTAL_1="21" TOTAL_2="21" VAR="0.48809523809523797" WEIGHT="15.39798184200464"/>
<DICH_DATA CI_END="1.3510724380256207" CI_START="0.029606110578684966" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.13067863443390323" LOG_CI_START="-1.5286186431059408" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="7353" O_E="0.0" SE="0.9746794344808963" STUDY_ID="STD-James-1977" TOTAL_1="8" TOTAL_2="8" VAR="0.95" WEIGHT="8.320204458354"/>
<DICH_DATA CI_END="1.4406135210567637" CI_START="0.4285305737812697" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.15854748658448958" LOG_CI_START="-0.3680181876245156" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="7354" O_E="0.0" SE="0.30930728357249476" STUDY_ID="STD-Quitkin-1977" TOTAL_1="30" TOTAL_2="30" VAR="0.09567099567099568" WEIGHT="55.530987263734445"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="28.191954277873215" CI_END="1.0029832966046235" CI_START="0.7297476546913498" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8555259834697146" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="106" I2="43.24621896624674" I2_Q="36.54011583871795" ID="CMP-003.05" LOG_CI_END="0.0012937004652383082" LOG_CI_START="-0.13682729210047134" LOG_EFFECT_SIZE="-0.06776679581761652" METHOD="MH" NO="5" P_CHI2="0.02998998993542079" P_Q="0.11599051220232592" P_Z="0.05444887934342441" Q="14.182187879711027" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1750331424487183" TOTALS="SUB" TOTAL_1="377" TOTAL_2="369" WEIGHT="1000.0" Z="1.9232482576755292">
<NAME>Adverse events (medium term)</NAME>
<GROUP_LABEL_1>Penfluridol</GROUP_LABEL_1>
<GROUP_LABEL_2>Typical AP oral</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Penfluridol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Typical AP depot</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.1056090312263697" CI_END="1.0240444741870836" CI_START="0.7351496199474888" DF="2" EFFECT_SIZE="0.8676554074100851" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.010318818431422433" LOG_CI_START="-0.13362426295015625" LOG_EFFECT_SIZE="-0.061652722259366854" NO="1" P_CHI2="0.948565427363429" P_Z="0.09316044299292517" STUDIES="3" TAU2="0.0" TOTAL_1="55" TOTAL_2="59" WEIGHT="100.00000000000001" Z="1.6789569045959623">
<NAME>needing antiparkinsonism medication</NAME>
<DICH_DATA CI_END="1.025169324079757" CI_START="0.7249172247473037" EFFECT_SIZE="0.8620689655172413" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="29" LOG_CI_END="0.010795602406657992" LOG_CI_START="-0.13971158086049498" LOG_EFFECT_SIZE="-0.0644579892269185" ORDER="7355" O_E="0.0" SE="0.08840866447369841" STUDY_ID="STD-Ionescu-1983" TOTAL_1="30" TOTAL_2="30" VAR="0.007816091954022983" WEIGHT="91.46756857926299"/>
<DICH_DATA CI_END="1.6570724609520653" CI_START="0.517990474823226" EFFECT_SIZE="0.9264705882352942" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.21934149979143933" LOG_CI_START="-0.2856782262967485" LOG_EFFECT_SIZE="-0.0331683632526546" ORDER="7356" O_E="0.0" SE="0.29665108699216336" STUDY_ID="STD-Iqbal-1978" TOTAL_1="17" TOTAL_2="21" VAR="0.08800186741363208" WEIGHT="8.12390631969336"/>
<DICH_DATA CI_END="13.366995426866405" CI_START="0.074811127562002" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.126033799470454" LOG_CI_START="-1.126033799470454" LOG_EFFECT_SIZE="0.0" ORDER="7357" O_E="0.0" SE="1.3228756555322954" STUDY_ID="STD-James-1977" TOTAL_1="8" TOTAL_2="8" VAR="1.75" WEIGHT="0.4085251010436701"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.598004635829613" CI_START="0.04450811651697542" DF="0" EFFECT_SIZE="0.4523809523809524" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.6625694048006385" LOG_CI_START="-1.3515607836907813" LOG_EFFECT_SIZE="-0.3444956894450715" NO="2" P_CHI2="1.0" P_Z="0.502563158109723" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="19" WEIGHT="99.99999999999999" Z="0.6704622650508589">
<NAME>insomnia</NAME>
<DICH_DATA CI_END="4.598004635829613" CI_START="0.04450811651697542" EFFECT_SIZE="0.4523809523809524" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6625694048006385" LOG_CI_START="-1.3515607836907813" LOG_EFFECT_SIZE="-0.3444956894450715" ORDER="7358" O_E="0.0" SE="1.183110042825089" STUDY_ID="STD-Doongaji-1988" TOTAL_1="21" TOTAL_2="19" VAR="1.399749373433584" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="115.72929405345836" CI_START="0.3499189042826871" DF="0" EFFECT_SIZE="6.363636363636363" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-003.05.03" LOG_CI_END="2.0634433039428495" LOG_CI_START="-0.4560325942307859" LOG_EFFECT_SIZE="0.8037053548560318" NO="3" P_CHI2="1.0" P_Z="0.21113690556014042" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="19" WEIGHT="100.0" Z="1.2504454206858584">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="115.72929405345836" CI_START="0.3499189042826871" EFFECT_SIZE="6.363636363636363" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0634433039428495" LOG_CI_START="-0.4560325942307859" LOG_EFFECT_SIZE="0.8037053548560318" ORDER="7359" O_E="0.0" SE="1.479952614194029" STUDY_ID="STD-Doongaji-1988" TOTAL_1="21" TOTAL_2="19" VAR="2.1902597402597404" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1737832403171855" CI_END="4.928310676750443" CI_START="0.06620925208391681" DF="1" EFFECT_SIZE="0.5712265434526208" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="18" I2="53.997253201101785" ID="CMP-003.05.04" LOG_CI_END="0.6926980775949843" LOG_CI_START="-1.1790813179888298" LOG_EFFECT_SIZE="-0.24319162019692267" NO="4" P_CHI2="0.1403805808016837" P_Z="0.6105433124284129" STUDIES="2" TAU2="1.5454812664176265" TOTAL_1="38" TOTAL_2="38" WEIGHT="100.0" Z="0.5092980701171193">
<NAME>lethargy</NAME>
<DICH_DATA CI_END="0.6510902258158527" CI_START="0.11850967925447514" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="18" LOG_CI_END="-0.1863588242447209" LOG_CI_START="-0.9262461772898536" LOG_EFFECT_SIZE="-0.5563025007672873" ORDER="7360" O_E="0.0" SE="0.4346134936801766" STUDY_ID="STD-Ionescu-1983" TOTAL_1="30" TOTAL_2="30" VAR="0.18888888888888888" WEIGHT="69.70159831260831"/>
<DICH_DATA CI_END="64.26151584089634" CI_START="0.14005271867976013" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8079509657466573" LOG_CI_START="-0.8537084563073322" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="7361" O_E="0.0" SE="1.563471919941143" STUDY_ID="STD-James-1977" TOTAL_1="8" TOTAL_2="8" VAR="2.444444444444444" WEIGHT="30.29840168739168"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3183556381700692" CI_START="0.0689911719154621" DF="0" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-003.05.05" LOG_CI_END="0.12003258086541281" LOG_CI_START="-1.1612064778669184" LOG_EFFECT_SIZE="-0.5205869485007528" NO="5" P_CHI2="1.0" P_Z="0.11122157081228023" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="19" WEIGHT="100.0" Z="1.5927264516781254">
<NAME>lack of facial expression</NAME>
<DICH_DATA CI_END="1.3183556381700692" CI_START="0.0689911719154621" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.12003258086541281" LOG_CI_START="-1.1612064778669184" LOG_EFFECT_SIZE="-0.5205869485007528" ORDER="7362" O_E="0.0" SE="0.7526061653349982" STUDY_ID="STD-Doongaji-1988" TOTAL_1="21" TOTAL_2="19" VAR="0.5664160401002507" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="312.4173614293384" CI_START="1.1555055658507298" DF="0" EFFECT_SIZE="18.999999999999996" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" ID="CMP-003.05.06" LOG_CI_END="2.494735160171501" LOG_CI_START="0.06277204173415661" LOG_EFFECT_SIZE="1.2787536009528289" NO="6" P_CHI2="1.0" P_Z="0.039289468260760824" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="2.0611422796402246">
<NAME>hypersalivation</NAME>
<DICH_DATA CI_END="312.4173614293384" CI_START="1.1555055658507298" EFFECT_SIZE="19.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.494735160171501" LOG_CI_START="0.06277204173415661" LOG_EFFECT_SIZE="1.2787536009528289" ORDER="7363" O_E="0.0" SE="1.4285471741816855" STUDY_ID="STD-Ionescu-1983" TOTAL_1="30" TOTAL_2="30" VAR="2.0407470288624787" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.8521044735880112" CI_END="2.6390475523190515" CI_START="0.36036489547056494" DF="1" EFFECT_SIZE="0.9752025919434921" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" I2="74.04016410103856" ID="CMP-003.05.07" LOG_CI_END="0.42144721573111665" LOG_CI_START="-0.4432575219270774" LOG_EFFECT_SIZE="-0.01090515309798037" NO="7" P_CHI2="0.0496836652021575" P_Z="0.9605719580483967" STUDIES="2" TAU2="0.38280410351244876" TOTAL_1="51" TOTAL_2="49" WEIGHT="100.0" Z="0.04943585107633734">
<NAME>fatigue</NAME>
<DICH_DATA CI_END="3.60909485931427" CI_START="0.7623478591537332" EFFECT_SIZE="1.6587301587301588" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.5573982969487681" LOG_CI_START="-0.11784681496178592" LOG_EFFECT_SIZE="0.21977574099349112" ORDER="7364" O_E="0.0" SE="0.3966423212534708" STUDY_ID="STD-Doongaji-1988" TOTAL_1="21" TOTAL_2="19" VAR="0.15732513100934153" WEIGHT="47.76537556308982"/>
<DICH_DATA CI_END="1.1531481274998097" CI_START="0.3121888605764218" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.061885098121928904" LOG_CI_START="-0.5055825973546417" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="7365" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Ionescu-1983" TOTAL_1="30" TOTAL_2="30" VAR="0.1111111111111111" WEIGHT="52.23462443691018"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0822276575033494" CI_END="1.780662933096928" CI_START="0.08131545397800988" DF="1" EFFECT_SIZE="0.38051992692445336" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="7.598000007969199" ID="CMP-003.05.08" LOG_CI_END="0.25058171836829257" LOG_CI_START="-1.089826909023815" LOG_EFFECT_SIZE="-0.4196225953277613" NO="8" P_CHI2="0.2982001902490109" P_Z="0.2197640262397822" STUDIES="2" TAU2="0.11885139567868643" TOTAL_1="51" TOTAL_2="49" WEIGHT="100.0" Z="1.227155894306325">
<NAME>tremors</NAME>
<DICH_DATA CI_END="3.2303079734614215" CI_START="0.11262690892131588" EFFECT_SIZE="0.6031746031746031" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5092439293895648" LOG_CI_START="-0.9483578350631079" LOG_EFFECT_SIZE="-0.21955695283677157" ORDER="7366" O_E="0.0" SE="0.8562024916845998" STUDY_ID="STD-Doongaji-1988" TOTAL_1="21" TOTAL_2="19" VAR="0.7330827067669172" WEIGHT="72.76853468902205"/>
<DICH_DATA CI_END="1.9774190029426781" CI_START="0.006243329812231785" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.29609870339830113" LOG_CI_START="-2.204583722276951" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="7367" O_E="0.0" SE="1.4689132354192893" STUDY_ID="STD-Ionescu-1983" TOTAL_1="30" TOTAL_2="30" VAR="2.1577060931899643" WEIGHT="27.23146531097796"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.012895214105476" CI_END="16.62477275533867" CI_START="0.335231436045767" DF="1" EFFECT_SIZE="2.360751245833988" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="1.2731044560087215" ID="CMP-003.05.09" LOG_CI_END="1.2207557176276558" LOG_CI_START="-0.47465526253262164" LOG_EFFECT_SIZE="0.37305022754751715" NO="9" P_CHI2="0.3142105106207369" P_Z="0.3884000972174585" STUDIES="2" TAU2="0.025604725242842984" TOTAL_1="38" TOTAL_2="38" WEIGHT="100.0" Z="0.8625224431995647">
<NAME>difficulty with visual accomodation</NAME>
<DICH_DATA CI_END="129.92776744614594" CI_START="0.3771326250203609" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1137019760147355" LOG_CI_START="-0.423505895986222" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="7368" O_E="0.0" SE="1.490368463394884" STUDY_ID="STD-Ionescu-1983" TOTAL_1="30" TOTAL_2="30" VAR="2.2211981566820276" WEIGHT="44.14283430845773"/>
<DICH_DATA CI_END="13.366995426866405" CI_START="0.074811127562002" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.126033799470454" LOG_CI_START="-1.126033799470454" LOG_EFFECT_SIZE="0.0" ORDER="7369" O_E="0.0" SE="1.3228756555322954" STUDY_ID="STD-James-1977" TOTAL_1="8" TOTAL_2="8" VAR="1.75" WEIGHT="55.85716569154228"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6082068584809363" CI_END="1.0203573755040827" CI_START="0.032332279913302224" DF="1" EFFECT_SIZE="0.1816328171790561" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" I2="0.0" ID="CMP-003.05.10" LOG_CI_END="0.008752308062000119" LOG_CI_START="-1.4903636699985532" LOG_EFFECT_SIZE="-0.7408056809682766" NO="10" P_CHI2="0.4354639386950786" P_Z="0.052735782698727654" STUDIES="2" TAU2="0.0" TOTAL_1="51" TOTAL_2="49" WEIGHT="100.0" Z="1.937078218749855">
<NAME>rigidity</NAME>
<DICH_DATA CI_END="2.6584193098090045" CI_START="0.03421390302993424" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.42462348284221657" LOG_CI_START="-1.465797379843722" LOG_EFFECT_SIZE="-0.5205869485007528" ORDER="7370" O_E="0.0" SE="1.1104425724759102" STUDY_ID="STD-Doongaji-1988" TOTAL_1="21" TOTAL_2="19" VAR="1.2330827067669172" WEIGHT="62.88592639180584"/>
<DICH_DATA CI_END="1.3074563269125963" CI_START="0.004525703567694904" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.11642719100191871" LOG_CI_START="-2.344313895615592" LOG_EFFECT_SIZE="-1.1139433523068367" ORDER="7371" O_E="0.0" SE="1.4454514951439552" STUDY_ID="STD-Ionescu-1983" TOTAL_1="30" TOTAL_2="30" VAR="2.0893300248138957" WEIGHT="37.11407360819416"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>